

Phytoalexins in cancer prevention

Donato F. Romagnolo¹, Cindy D. Davis², John A. Milner²

¹Department of Nutritional Sciences and Arizona Cancer Center, The University of Arizona, Tucson, Arizona, 85721-0038, USA,

²Nutritional Sciences Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 6130 Executive Boulevard, Rockville MD 20892, USA

TABLE OF CONTENTS

1. Abstract
2. Introduction
3. Phytoalexins and cancer prevention mechanisms
 - 3.1. Antimicrobial activity
 - 3.2. Proliferation
 - 3.2.1. Cruciferous phytoalexins
 - 3.2.2. Deoxyanthocyanidins
 - 3.2.3. Glycoalkaloids
 - 3.2.4. Stilbenes
 - 3.2.5. Phenolic coumarins and garlic phytoalexins
 - 3.3. Apoptosis
 - 3.3.1. Stilbenes
 - 3.3.2. Phenolic coumarins
 - 3.3.3. Glycoalkaloids
 - 3.3.4. Garlic phytoalexins
 - 3.3.5. Di-terpenes
 - 3.4. Invasion and metastasis
 - 3.4.1. Glycoalkaloids
 - 3.4.2. Garlic phytoalexins
 - 3.4.3. Stilbenes
 - 3.4.4. Phenolic coumarins
 - 3.5. Hormonal regulation
 - 3.5.1. Soy phytoalexins
 - 3.5.2. Phenolic coumarins
 - 3.5.3. Bean phytoalexins
 - 3.5.4. Arylbenzofurans
 - 3.5.5. Stilbenes
 - 3.6. Modulation of phase I/II metabolizing enzyme activities
 - 3.7. Bioavailability of phytoalexins
4. Summary and perspective
5. Acknowledgements
6. References

1. ABSTRACT

Plant phytoalexins are a class of low molecular weight compounds that accumulate in response to biotic and abiotic elicitors such as pathogens, wounding, freezing, UV light, and exposure to agricultural chemicals. Phytoalexins have been identified in at least 75 plants including cruciferous vegetables, soybean, garlic, tomato, rice, beans, and potatoes suggesting plants may be a rich source of cancer-fighting compounds. Preclinical evidence suggests these compounds possess anticancer properties including an inhibition of microbial activity, cell proliferation, invasion and metastasis, hormonal stimulation, and stimulatory effects on expression of metabolizing enzymes. This review highlights the plausible molecular mechanisms through which phytoalexins regulate biological processes that can impinge cancer development. Targets of phytoalexins include signal transduction pathways, transcription factors, cell cycle

checkpoints, intrinsic and extrinsic apoptotic pathways, cell invasion and matrix metalloproteinase, nuclear receptors, and the phase II detoxification pathway. Additional research should address physiological relevant dietary concentrations, combinations of phytoalexins and interactions with other dietary compounds, duration of exposure, and tissue specificity as variables that influence the effectiveness of phytoalexins on normal and cancerous processes.

2. INTRODUCTION

Phytoalexins are a class of low molecular weight compounds that accumulate in plants in response to biotic and abiotic elicitors including pathogens, stress due to wounding, freezing, UV light, and exposure to agricultural chemicals (1-2). For example, the exposure to yeast elicitors stimulates the production of the pterocapan phytoalexin medicarpin from phenylalanine and malonyl-

Table 1. Selected phytoalexins in common food plants and herbs

Plant	Species	Phytoalexins
Alfalfa	<i>Medicago Sp.</i>	Medicarpin, vesitol, sativan
Babchi	<i>Psoralea C.</i>	Psoralidin
Bean	<i>Phaseolus V.</i>	Phaseolin, kievitone, phaseollidin, coumestrol, psoralidin
Blueberries	<i>Vaccinium Sp.</i>	Resveratrol
Celery	<i>Apium G.</i>	Furanocoumarins
Cruciferous	<i>Brassica Sp.</i>	Camalexin, brassinin, brassalexin, brassilexin, caulilexin, erucalexin, isobrassinin, cyclobrassinin, 1-methoxybrassinin, spiobrassinin, 1-methoxyspirobrassinin, 1-methoxyspirobrassinol, rapalexin, rutalexin, glucoraphanin
Eggplant	<i>Solanum M.</i>	Lubimin
Garlic	<i>Allium s.</i>	Allicin, aliin
Grapes	<i>Vitis Sp.</i>	Resveratrol, pterostilbene, viniferin
Pea	<i>Pisum S.</i>	Pisatin, cinnamylphenols
Peanut	<i>Arachis H.</i>	Resveratrol
Pepper	<i>Piper Sp.</i>	Capsidiol
Potato	<i>Solanum T.</i>	alpha-chaconine, alpha-solanine, rishitin
Rice	<i>Oryza S.</i>	Momilactone B
Sagebrush	<i>Artemisia Sp.</i>	Scopoletin
Sanfoins	<i>Onobrychis E.</i>	Enbenfuran III
Sorghum	<i>Sorghum sp.</i>	Apigeninidin, luteolinidin, coumestrol
Soybean	<i>Glycine M.</i>	Glyceollin (I, II, III), coumestrol
Tomato	<i>Solanum L.</i>	alpha-tomatine, rishitin

CoA in the legume *Medicago trunculata* (Barrel clover) (3). Because plants with increased levels of phytoalexins display improved resistance to various stresses, it is possible that these compounds may provide benefits in non-plant circumstances where stress might induce abnormalities including cancer (4).

The development of genetically engineered plants such as kiwis (5), apples (6), tomatoes (7), and brussel sprouts (8) that produce higher levels of resveratrol provides an example of potential strategies to increase the dietary intake of phytoalexins. Other plants that have been genetically engineered to increase the production of phytoalexins include peanut (9) and alfalfa (medicarpin) (10). Interestingly, phytoalexin compounds have been identified in at least 75 plant species including cruciferous vegetables, peas, soybean, grapes, peanut, garlic, tomato, and beans (Table 1). In *Brassica Sp.* alone, close to 40 phytoalexin compounds have been isolated (11). Therefore, plant phytoalexins represent a rich source of compounds for the development of functional foods with cancer prevention properties.

Several factors influence the content of phytoalexins in plants and include the stage of maturity at harvest. For example, the levels of tomato glycoalkaloids, which comprise the phytoalexin alpha-tomatine, decline from 20-50 mg/100 g in green tomatoes, to 1-3 mg/100 g as the fruit ripens (12). The content of alpha-chaconine and alpha-solanine, two phytoalexins found in potatoes, varies depending on the potato cultivar and it is higher in potato sprouts and potato cortex. Moreover, the content of phytoalexin can change in response to treatment. For example, synthetic elicitors have been developed as green pesticides to increase phytoalexin protection of growing fruits from attack by harmful pathogens (13). There is ample research evidence documenting that time of harvest, cultivar selection, growing conditions, and post-harvest processing impact the content of phytoalexins in plants, and consequently, the potential nutritional and cancer prevention properties of plant-derived foods (14).

Several classes of phytoalexins have been identified in plants. Many cruciferous phytoalexins are produced from tryptophan and include camalexin, brassinin, 1-methoxy-brassinin, cyclobrassinin, rapalexin, and rutalexin (15). 3-deoxyanthocyanidin phytoalexins are a rare type of flavonoid induced in Sorghum by *Colletotrichum*, the anthracnose fungus (16). Sorghum is the only reported dietary source of 3-deoxyanthocyanidin available for human consumption. The major components of the 3-deoxyanthocyanidins group include apigeninidin and luteolinidin (17). These compounds are structurally related to anthocyanidins except for the absence of C-3 hydroxylation in the C-ring.

Although adverse health consequences have been reported for glycoalkaloids, a selected group of glycoalkaloid phytoalexins have drawn attention because of their anticancer properties. Glycoalkaloids are nitrogen-containing steroidal glycosides and include alpha-solanine and alpha-chaconine from potatoes (*Solanum tuberosum*), and alpha-tomatine found in tomatoes (*Solanum lycopersicum*). Alpha-solanine and alpha-chaconine comprise more than 95% of the glycoalkaloid content in potatoes and differ only in the structure of the carbohydrate moiety attached to the 3-OH group of solanidine (18). Postharvest conditions can dramatically increase their content in potatoes by 300-fold (19).

Stilbenes are synthesized from coumaryl-CoA and three molecules of malonyl-CoA, and possess structural similarities to estrogen (20). Stilbene phytoalexins are structurally characterized by the presence of a 1,2-diphenylethylene nucleus and comprise monomeric (resveratrol, pterostilbene) and dimeric (viniferin) compounds (21). Resveratrol (3,5,4'-trihydroxy-trans-stilbene) is found predominantly in grapes, peanuts and blueberries. Pterostilbene (trans-3,5-dimethoxy-4'-hydroxy-stilbene) is found in grapes, grape leaves, some berries, and extracts of heartwood of *Pterocapus marsupium* used in Ayurvedic medicine. Stilbenes synthesis in grapes is influenced by grape variety with red grapes containing more stilbenes than white grapes, and




Figure 1. Phytoalexins in nutrition and cancer prevention. Phytoalexins are a class of low molecular weight compounds that accumulate in plants in response to biotic and abiotic elicitors including pathogens, stress due to wounding, freezing, UV light, and exposure to agricultural chemicals. They modulate cellular processes that impinge on cancer including proliferation, apoptosis, invasion and metastasis, hormonal regulation, and expression/activity of Phase I and II metabolizing enzymes. Existing data suggest that opportunities exist for the development of cancer prevention strategies based on dietary phytoalexins.

growing conditions with stilbenes content increasing with elevation) (22).

Phenolic coumarins include psoralidin which is found in *Psoralea coryfolia*, a herbal plant used in traditional Chinese medicine for the cure of endocrine disorders and depression. Psoralidin is also one among several phytoalexins (phaseolin, kievitone, phaseollidin, coumestrol) isolated from *Phaseolus vulgaris* (23). Psoralidin possesses an isopentenyl group at the C-2 position of coumestrol.

Phytoalexins have also been isolated from garlic (*Allium sativum* L.) and include the thiosulfinate allicin, which originates from alliin by action of the enzyme alliinase upon crushing of garlic cloves. Alliin is a sulfoxide that is synthesized from the amino acid cysteine (24). Diterpene phytoalexins are composed of isoprene units and include momilactones, oryzalexins, and phytocassanes found in rice (*Oryza sativa*) seedlings (25).

Although much of the research dealing with the health effects of soy products has focused on the isoflavonoids genistein and daidzein, many phytoalexins with health benefiting properties are also found in soy. Their content varies greatly in response to stress factors and physical stimuli. The enrichment of the soybean phytoalexins coumestrol and glyceollin through inoculation with food-grade, non toxin producing *Aspergillus* Sp. (*A. sojae*, *A. oryza*) has been proposed as a strategy to increase the health benefits of fermented soybean foods (26).

Glyceollins are pterocarpan compounds induced in soybean in response to exposure to various elicitors including the fungus *Diaporthe phaseolorum* f. sp.

meridionalis (27) and disease-inducing herbicides (28). They share the core structure with coumestrol and consist primarily of three major isomers (I, II, and III) derived from the parent isoflavone daidzein through the intermediate glycinol that is prenylated to produce glyceollidin I and II followed by cyclization. Other pterocarpan phytoalexins include those isolated from *Phaseolus vulgaris* L. Analysis of extracts from red kidney bean elicited with *Aspergillus sojae* achieved levels of the pterocarpan kievitone at about 1200 mg/Kg and phaseollin at about 228 mg/Kg (29).

Finally, 2-arylbenzofurans are phytoalexins found in rice, leguminose, *Morus alba* and other crops. They have been shown to protect plants against invasion by pathogens and insects, possess cytotoxic activities against various tumor cells (30), and modulate endocrine functions (31).

The objective of this review is to summarize and discuss experimental evidence related to the anticancer effects of phytoalexins with specific interest on modulation of antimicrobial activities, proliferation, apoptosis, invasion and metastasis, hormonal regulation, and expression/activity of Phase I and II metabolizing enzymes (Figure 1). The existing data suggest that opportunities exist for the development of cancer prevention strategies based on dietary phytoalexins (Table 2). Nevertheless, before phytoalexin-based diets can be formulated for cancer prevention, future studies need to better identify molecular targets; the effects of duration, dose, and timing of exposure; tissue-specific responses and effects in normal versus cancer cells.

Table 2. Effects of selected phytoalexins on cancer processes

Cancer Process/ Phytoalexin	Cancer Model	Dose	Mechanisms of action	Reference
Proliferation				
<i>Cruciferous phytoalexins</i>				
Isobrassinin	Hela (cervix), MCF-7 (breast)	30 micromol/L	Growth inhibition	58
Brassinin	BALB/c/breast	1-10 micromol/L	Reduces DMBA-induced mammary lesions	53
	CD-1 mice/skin	1% diet	Reduces incidence DMBA/TPA skin tumors	54
	BALB/c/breast	1-10 micromol/L	Reduces DMBA-induced mammary lesions	55
	MMTV-Neu mice/breast	400 mg/kg	Trend to tumor regression in combination with Paclitaxel; inhibits IDO enzyme (EC50=38 micromol/L)	59
Cyclobrassinin	BALB/c/breast	1-10 micromol/L	Reduces DMBA-induced mammary lesions	53
1-methoxy- Brassinin	T-Jurkat/leukemia	1-100 micromol/L	Growth inhibition, induces sub-G0/G1 arrest	56
<i>Deoxyanthocyanidins</i>				
3-deoxyantho-cyanidins (Luteolinidin, Apigeninidin)	HL-60 (leukemia), HepG2 (liver)	50-200 micromol/L	Growth inhibition	60
<i>Glycoalkaloids</i>				
alpha-Chaconine	AGS/gastric, HepG2/liver	10 microg/ml	Growth inhibition	62
	HT-29/colon, HepG2/liver	1-10 microg/ml	Growth inhibition	61
alpha-solanine	AGS/gastric, HepG2/liver	10 microg/ml	Growth inhibition	62
	HT-29/colon, HepG2/liver	1-10 microg/ml	Growth inhibition	61
alpha-tomatine	HT-29/colon, HepG2/liver	1-10 microg/ml	Growth inhibition	61
<i>Stilbenes</i>				
Resveratrol	MCF-7, MDA-MB-231/ breast	10-25 micromol/L	Induces S-phase arrest; inhibits Akt activation, mTOR, and p70S6K	76
	Colorectal cancer tissues	0.5-1.0 g/d	Reduces Ki-67 staining for 8 d	199
	A431/epidermoid	1-25 micromol/L	Induces phase G1 arrest; reduces cyclin D1	67
		10-25 micromol/L	Reduces cyclin E, cdk2/4/6; increases p21 and hyperphosphorylated Rb	67
		25-100 micromol/L	Induces G1 arrest, p27, p21, and hypophosphorylated Rb; reduces cyclin A, D1, cdk6, MEK-1, ERK1/2, AP-1	68
	HL60/leukemia, SW480 colon, HCE7 esophageal	300 micromol/L	S-phase arrest	70
	□ML/Leukemia	10-50 micromol/L	Induces S-phase arrest, NFkappaB activation	69
	HT29/colon	50-100 micromol/L	Induces G2-phase arrest; inactivates 34/cdc2	77
	Ovcar-3/ovary	30-50 micromol/L	Induces S-phase arrest; activates ATM/ATR/chk, Cdc25C	74
	Caco-2, HCT-116/colon	50 micromol/L	Induces S-phase arrest; reduces cyclin D1 and cdk4	71
	HCT116/colon	10 micromol/L	Induces S-phase arrest; reduces Tyr phosphorylated EGFR, HER-2, HER-3, and IGF-1R	96
	HCT116/SCID mice xenografts	150 mg/kg/d	Reduces NFkappaB activity and tumor growth	96
	Neuro-2a/neuroblastoma	25 micromol/L	Induces S-phase arrest; inhibits proliferation	72
	s.c. neuro-2a in AJ mice	40 mg/kg	Reduces tumor growth; increases survival	72
	HT29/colon	100-150 micromol/L	Induces G0/G1 arrest; induces p27 and p53; reduces cyclin D1	95
Pterostilbene	MIA PaCa, PANC-1/pancreas	25-75 micromol/L	Induces S-phase arrest	80
	RAW 264.7/macrophage	1-20 micromol/L	Inhibits activation of NFkappaB, PI3K/Akt, ERK1/2, and p38	86
	ICR mice/ACF	50-250 ppm	Reduces AOM-induced ACF, GSK3beta, Wnt/beta-catenin, Ras, PI3K/Akt, and EGFR	84
	F344 rats/colon	15 mg/kg	Reduces AOM-induced ACF; inhibits PCNA and iNOS	82
		40 ppm	Reduces ACF, PCNA, beta-catenin, cyclin D1, iNOS, COX-2, TNFalpha, IL-1beta, and IL-4	83
	HT-29/colon	10-50 micromol/L	Reduces proliferation, cyclin D1, c-Myc, iNOS, and COX-2	87
	T24/bladder	50-100 micromol/L	Induces arrest in G0/G1 and S-phase; reduces cyclin A, B, D1, and pRb	81
<i>Phenolic Coumarins</i>				
Psoralidin	RAW 264.7/macrophage	10-30 micromol/L	Inhibits LPS-induced PI3K, Akt, IKK phosphorylation, NFkappaB, and iNOS	88
	PC-3, DU-145/prostate	45-60 micromol/L	Inhibits NFkappaB, PI3K, and Akt	89
	PC-3 /prostate, nude mice	15-25 mg/kg	Inhibits tumor growth	90
<i>Garlic thiosulfates</i>				
Allicin	MCF-7, HT-29, Ishikawa	10-40 micromol/L	Inhibits growth; induces G0/G1 and G2/M arrest	91
Apoptosis				
Stilbene				

Phytoalexins in cancer prevention

Resveratrol	HT-29/colon	100-150 micromol/L	Induces Fas, TRAIL, and FKHRL1	95
		100 micromol/L	Increases ROS; activates AMPK	105
	LNCaP/prostate	20 micromol/L	Increases FOXO, Bim, TRAIL, DR4, DR5, and p27; reduces cyclin D1, PI3K, Akt, and mTOR	102
	HCT116/colon	50 micromol/L	Increases p53, Bax, DR4, and Fas	101
		10 micromol/L	Increases apoptotic nuclei	96
	HCT116/ SCID mice	150 mg/kg/d	Increases mitotic index; reduces NFkappaB activity and tumor volume	96
	B16/melanoma	25-100 micromol/L	Increases p53, G1-phase arrest	65
	B6D2F1 mice	12.5-50 mg/kg	Increases survival; reduces tumor size	65
	HL60/leukemia	20 micromol/L	Induces JNK and FasL signaling	104
	AML/leukemia	10-50 micromol/L	Induces caspase-3 and PARP	69
	B-myeloma/lymphoma	30 micromol/L	Induces ATM, Chk1, Chk2, Bax, and p38 MAPK	73
	MDA-MB-231/breast	10-100 micromol/L	Induces caspase-3 and PARP	98
		50-100 micromol/L	Induces caspase-8/9 and Bax	99
	UMSCC-22B/head, neck	1-100 micromol/L	Induces p53-Ser15, ERK1/2, and BAD	97
	Prostate PC-3/Balb-c mice	30 mg/kg/d, 3d/w for 3 wks	Reduces tumor volume, Bcl-2, cyclin D1; Increases TRAIL-R1/DR4, TRAIL-R2/DR5, Bax, and p27	108
Pterostilbene	SK-MEL-2, MeWo/melanoma	50-75 micromol/L	Induces caspase 3/7 and VEGF	110
	NCI-H460, SK-MES-1, lung	50-75 micromol/L	Induces caspase 3/7	111
	MIA PaCa, PANC-1	50 micromol/L	Reduces caspase 3/7	80
	AGS/gastric	20-100 micromol/L	Induces cyt.c release, PARP cleavage, Bad, Bax, FasL, P53, and p21; Reduces phosphorylated Rb	113
	ICR mice/ACF	50-250 ppm	Induces caspase 3/9, PARP, FasL, and Bax,	81
	T24/bladder	100 micromol/L	Induces caspase-3	102
<i>Phenolic coumarins</i>				
Psoralidin	PC3, DU-145	45-60 micromol/L	Reduces Bcl-2, Bcl-xL, and surviving	89
	PC3, DU-145	45-60 micromol/L	Induces SAPK, Bax, caspase-3; inhibits EGF-induced Bcl-2 and surviving	90
	PC3, DU-145	45-60 micromol/L	Reduces TNFalpha, Bcl-2; induces caspase 9/3, PARP, Fas, FasL, DR4, and DR5	117
<i>Glycoalkaloids</i>				
alpha-Chaconine	HT-29/colon	5 mg/ml	Induces caspase-3; inhibits ERK1/2	18
<i>Garlic thiosulfinates</i>				
Allicin	HCT-116	10 micromol/L	Reduces Bcl-2/Bax ratio; increases cyt.c release	125
	HL-60	5-20 micromol/L	Induces cyt.c release, caspase 9/3, and DNA fragmentation	126
	SiHa/cervix	50-100 micromol/L	Activates caspase 3/8/9 and PARP	124
<i>Di-terpenes</i>				
Momilactone B	MCF-7/breast	25-100 micromol/L	Inhibits Jack/Stat5, Bcl-2, pRb, and cyclin D1; activates bax and p21	128
	Jurkat/lymphoma	0.3-6 micromol/L	Activates caspase-3, PARP, release of cyt.c; reduces phosphorylated Bad	129
	HT-29, SW620/colon	0.5-10 micromol/L	Reduces survival	130
<i>Glycoalkaloids</i>				
alpha-Chaconine	Aortic/endothelial	3-4 microg/ml	Inhibits invasion, tube formation, MMP-2, JNK, and PI3K,	132
	A549/lung	1.25-1.5 microg/ml	Inhibits JNK, NFkappaB, MMP-2, MMP-9, PI3K/Akt, and NFkappaB	133
alpha-Solanine	A2058/melanoma	9-18 micromol/L	Inhibits cell migration, invasion, MMP-2, MMP-9, JNK, PI3K, Akt, and NFkappaB	132
<i>Garlic thiosulfinates</i>				
Allicin	HUVEC/endothelial	0.01-1 microg/ml	Inhibits monocyte adhesion and ICAM-1	135
<i>Stilbenes</i>				
Resveratrol	MCF-7/breast	5-10 micromol/L	Reduces ERK1/2 and heregulin-induced MMP-9	139
	PC3, nude mice/prostate	30 mg/kg	Reduces VEGF, blood vessels, MMP-2, and MMP-9	108
Pterostilbene	HepG2/liver	25-50 micromol/L	Reduces TPA-induced invasion, MMP-9, JNK, p38, PI3K, Akt, and NFkappaB	136
	HepG2/nude mice	50-250 mg/kg	Inhibits metastasis to lung and MMP-9 activity	136
	MCF-7/breast	5-30 micromol/L	Reduces invasion, MMP-9, p38, and Akt	137
<i>Phenolic coumarins</i>				
Coumestrol	MDA-MB-231/breast	2.5-10 micromol/L	Inhibits invasion	140
	Min/+ mice/colon	0.01% diet	Restores E-cadherin/beta-catenin junctions	141
Scopoletin	Human endothelial	30-100 micromol/L	Inhibits tube formation, VEGF actions, and VEGFR2	142

Phytoalexins in cancer prevention

		30-100 micromol/L	Inhibits ERK1/2, p38, and eNOS	142
Hormonal Regulation				
<i>Soy phytoalexins</i>				
Glyceollin	ER binding/breast	6-16 micromol/L	Reduces transactivation of ER (IC ₅₀ ERalpha is lower than IC ₅₀ ERbeta)	143
	ER binding/MCF-7 (breast)	1-25 micromol/L	Reduces transactivation of ER (IC ₅₀ ERalpha lower than IC ₅₀ ERbeta)	144
	Ishikawa (endometrium)	1-25 micromol/L	Inhibits proliferation	144
	MCF-7 (breast), BG-1 (ovary)/ xenografts/nu-nu mice	20 mg/kg	Reduces mammary and ovarian tumor burden; lowers PR expression	145
	Postmenopausal female monkeys/breast	134 mg/d	Reduces estrogen-induced proliferation, TFF1, and PR	148
	LNCaP/prostate	5-25 micromol/L	Inhibits estrogen-induced growth, PSA, IGF-1R, and NKX3.1	152
	MCF-7/xenografts (breast), BG-1 (ovary)	20 mg/kg/d	Inhibits tumor growth, PR, SDF-1, and colony formation	153
(-)-glyceollin I	MCF-7/breast	10 micromol/L	Reduces PR; induces NGFR	154
<i>Phenolic coumarins</i>				
Coumestrol	ER binding assay/breast	35-100 nanomol/L	Binds ER: IC ₅₀ ERbeta lower than IC ₅₀ ERalpha	143
	MCF-7/breast	10 micromol/L	Inhibits estradiol (1 nanomol/L)-induced growth	157
	Alpk:AP rats/uterus	60 mg/kg/d	Induces uterine hyperplasia	158
	Ishikawa/endometrium	10-20 nanomol/l	Transactivates ERalpha and ERbeta	161
	Adult males/testicular cancer	19-84 microg/1,000 kcal	Increases risk, less than 19 or higher than 84 microg/1,000 kcal	162
	Male of 61 years/prostate	45-67 microg/d	Reduces risk (OR=0.48)	163
	Min/+ mice/colon	0.01% diet	Reduces tumor burden; restores E-cadherin/beta-catenin junctions	141
<i>Bean phytoalexins</i>				
Kievitone	ER binding assay/breast	0.1-10 micromol/L	IC ₅₀ ERalpha higher than IC ₅₀ ERbeta; reduces MCF-7 colony formation	29
	MCF-7/breast	1-18 micromol/L	Inhibits estrogen- and growth factor-induced proliferation	164
Phaseollin	ER binding assay/breast	0.1-10 micromol/L	IC ₅₀ ERalpha higher than IC ₅₀ ERbeta; reduces MCF-7 colony formation	164
<i>Arylbenzofurans</i>				
Enbenfuran III	MCF-7/breast	1-10 micromol/L	Inhibits growth and Bcl-2; induces G1 arrest and Bax	165
<i>Stilbenes</i>				
Resveratrol	MCF-7/breast	10 micromol/L	Induces p53 activity; reduces Bcl-2/Bax, NFkappaB	168
		10-75 micromol/L	Antagonizes activity of ERalpha at selected ERE	167
		20 micromol/L	Prevents AhR-dependent repression of BRCA-1	170
		10-20 micromol/L	Reduces AhR-binding to XRE	172
	LNCaP/prostate	10 micromol/L	Reduces AR binding to ARE in PSA promoter	171
		1-25 micromol/L	Reduces estrogen and androgen-induced growth	173
	MCF-10F/breast	25 micromol/L	Inhibits estrogen- and TCDD-induced DNA adducts	169
Detoxification				
<i>Cruciferous phytoalexins</i>				
Brassicinin, cyclo-brassicinin	Organ-cultures	0.1 micromol/L	Induces QR	54
<i>Phenolic coumarins</i>				
Psoralidin	Hepa1c1c7/liver	0.2-0.8 microg/ml	Induces QR	178
<i>Garlic thiosulfates</i>				
Allicin	HCT116/colon	10 micromol/L	Activates Nrf2	125
	HUVEC/endothelial	15-20 micromol/L	Increases GSH levels and GCLM expression	180
	HepG2/liver	25-100 micromol/L	Reduces DNA damage by AFB1 and MMS	182
<i>Stilbenes</i>				
Resveratrol	Human subjects	1 g/d/4 wks	Induces GST-pi and UGT1A1	190
Glucoraphanin	SD rats/liver	120-240 mg/kg	Increases Phase-I (CYP1A1/2, 3A1/2, 2E1, 1A2, 2B1/2, 2C11)	194

3. PHYTOALEXINS AND CANCER PREVENTION MECHANISMS

3.1. Antimicrobial activity

The human body contains 100 times more microbes than mammalian cells. The amounts and types of microbes continue to be viewed as an important variable in many human conditions. They have been implicated in the

etiology of many different types of cancer. Infections due to bacteria, viruses and parasites have been estimated to cause 20-25% and 7-10% of cancer deaths in developing and industrialized countries, respectively (32). One mechanism whereby dietary phytoalexins may be protective against cancer is through their antimicrobial activity.

Helicobacter pylori (*H. pylori*), a gram-negative bacterium, causes one of the most widespread infections in humans. It afflicts up to 50% of the world's populations (33). In 1994, *H. pylori* was classified by the International Agency for Research on Cancer as a group I carcinogen and a definite cause of gastric cancer in humans (34). Epidemiologic studies have linked *H. pylori* infection with gastric adenocarcinoma (35) and colorectal adenomas (36). *CagA* is the strain-specific *H. pylori* gene that has been associated with development of both premalignant and malignant lesions (37).

Phytoalexins that have been investigated for their inhibitory effects on *H. pylori* include resveratrol, which has been reported to inhibit the growth of 15 different strains of *H. pylori* in vitro (38). These studies suggested that antimicrobial activity may contribute to resveratrol's cancer protective effects (39). Complex mixtures such as red wine extracts have also been shown to inhibit the growth of *cagA*⁺ strains of *H. pylori* in vitro (40).

Preincubation of MKN-45 human gastric cancer cells with resveratrol (1-100 micromol/L) significantly inhibited the secretion of interleukin (IL)-8 from *H. pylori* infected cells and suppressed *H. pylori*-induced ROS generation in a concentration dependent manner (41). IL-8 is one of the cytokines that mediate the gastric inflammatory response to *H. pylori* infections (42). Further evidence of the protective effects of grape compounds against *H. pylori* was provided by evidence that the addition of red wine in the drinking water significantly reduced the localization of bacteria and VacA to the surface of the gastric epithelium and prevented gastritis in *H. pylori*-infected mice (43).

Human studies have also suggested that wine consumption may inhibit *H. pylori* infection. A study of 10,537 subjects in England found an 11% lower risk of *H. pylori* infection in wine drinkers (3-6 glasses/wk) compared with those who drank no wine (OR=0.89, 95% CI=0.80-0.99), and higher wine consumption (more than 7 glasses/wk) was associated with a further 6% reduction in

the risk of infection (OR=0.83, 95% CI=0.64-1.07) (44). Similarly, in a sample of 3,608 Danish adults there was a lower rate of *H. pylori* infection among wine drinkers (OR=0.6, 95% CI 0.5-0.7) compared to non-drinkers (45). Since resveratrol is an important bioactive component in berries and peanuts, these studies suggest that resveratrol-rich diets may have preventative effects against *H. pylori* infection in humans, and possibly, one mechanism by which such compounds may exert anticancer properties.

Other food phytoalexins may also influence microbial populations. For centuries, garlic has been widely used as an antimicrobial agent against bacteria, viruses and fungi (46). Allicin and allyl-methyl plus methyl-allyl thiosulfinate from acetonic garlic extracts were shown to inhibit the in vitro growth of *H. pylori* (47). Allitridi is a proprietary garlic derivative and has been used to treat both systemic fungal and bacterial infections in China (48). A proteomic analysis revealed that the

bacteriostatic mechanisms of allitridi against *H. pylori* could be attributed to its inhibitory effects on a number of molecular targets associated with energy metabolism, and reduced biosynthesis of amino acids, proteins, mRNA, and fatty acids. Additionally, allitridi was found to suppress the production of virulence factors such as CagA, VacA and NapA leading to the pathogenic attenuation of *H. pylori* (49).

Animal and human studies also suggested that garlic components were protective against the adverse effects of *H. pylori* infection. A study that investigated the effect of various doses (1, 2, and 4% in the diet) of garlic extracts on *H. pylori*-induced gastritis in Mongolian gerbils revealed that gastritis was decreased in a dose-dependent manner compared with the control group, even though the number of viable *H. pylori* was unchanged (50). The Shandong Intervention Trial sought to determine whether any of three interventions with amoxicillin and omeprazole (1 g, 2 times/d for 2 wks), garlic supplement (aged garlic extract, 400 mg, 2 times/d, and steam-distilled garlic oil, 2 mg, 2 times/d for 7.3 years), or a vitamin supplement (100 IU vitamin E, 250 mg vitamin C, 27.5 microg selenium 2 times/d for 7.3 years) could reduce the prevalence of precancerous gastric lesions in Shandong Province in China, a region with high gastric cancer mortality rates and about 67% prevalence of *H. pylori* infection (51). Although long-term administration of garlic did not appear to influence the prevalence of *H. pylori* infection, garlic components may be protective against the adverse effects associated with infection. Other microbes may also be influenced by allyl sulfur compounds arising from garlic. For example, ear infections appear to be sensitive to the amount of garlic consumed confirming the physiological relevance of these phytoalexins as modifiers of microbial proliferation. Many foods may influence microbial activity as reviewed several years ago by Billings and Sherman (52).

3.2. Proliferation

3.2.1. Cruciferous phytoalexins

In organ culture, mammary glands incubated with brassinin and cyclobraassinin (1-10 micromol/L) had respectively, a 70% and 90% maximal reduction in the number of lesions compared to control glands. (53). Protective effects of brassinin against 7, 12-dimethylbenz (a)anthracene (DMBA)-induced mammary lesions in organ culture have been reported at concentrations as low as 0.1 micromol/L (54-55). Similarly, concentrations of 1 micromol/L for brassinin, 1-methoxybrassinin, (+/-)-spirobrassinin, (+/-)-1-methoxyspirobrassinin, and (+/-)-1-methoxyspirobrassinol were reported to markedly inhibit (60-70%) in vitro proliferation of T-lymphoblastic leukemia (56). In vivo, brassinin treatment during the promotion phase at a concentration of 1% reduced skin tumor incidence by 50% (53).

The treatment of solid tumors and leukemia cell lines with analogues of 1-methoxyspirobrassinol exerted cytostatic/cytotoxic effects, which were similar to those induced by the drugs cisplatin, etoposide, and doxorubicin

(57). Brassinin and isobrassinin, a regioisomer of brassinin, inhibited by 25-80% the growth of Hela, A431, and MCF-7 cell lines (58). Brassinin and its structural derivative 5-bromo-brassinin were reported to inhibit idolamine 2,3-dioxygenase (IDO), a pro-toleragenic enzyme involved in immune escape in cancer. The protective effects of brassinin and 5-bromo-brassinin on established breast tumors appeared to be dependent on coincident IDO expression since response to treatment was lost in IDO^{-/-} mice (59).

One of the mechanisms that contribute to the anticancer effects of cruciferous phytoalexins is induction of cell cycle arrest. For example, 1-methoxybrassinin was reported to induce cell cycle arrest with 90% of cells positioned in sub-G0/G1 after 72 h incubation in vitro (56).

3.2.2. Deoxyanthocyanidins

Studies that investigated the biological activities of 3-deoxyanthocyanidins reported luteolinidin and apigeninidin were more cytotoxic on human HL-60 and HepG2 cancer cells than the 3-hydroxylated anthocyanidin analogues pelargonidin and cyanidin. Because the production of 3-deoxyanthocyanidins can occur rapidly (about 3 d) in seedlings inoculated with fungi, the process of inoculation could be exploited for the large-scale enrichment of these phytoalexins in Sorghum products (60).

3.2.3. Glycoalkaloids

In vitro studies documented that glycoalkaloid phytoalexins effectively suppressed the growth of cervical, liver, lymphoma, stomach, and colon cancer cells. In particular, alpha-solanine, and alpha-chaconine isolated from potatoes (*Solanum tuberosum*), and alpha-tomatine found in tomatoes (*Solanum lycopersicum*) at concentrations of 1-10 mg/L inhibited by 60- 80% the growth of human colon (HT29) and liver (HepG2) cancer cells within 4 h with alpha-tomatine being the most active compound at lower concentrations (0.1 mg/L, 40% growth inhibition). These antiproliferative effects were stronger than those elicited by similar levels (1 mg/L) of the anticancer drugs doxorubicin and camptothecin (61). Compared to treatments with alpha-chaconine and alpha-solanine alone, their combination offered synergistic advantages against proliferation of HepG2 cells (62). These data suggested that combinations of phytoalexins may additively prevent proliferation of cancer cells.

3.2.4. Stilbenes

Resveratrol was reported to induce cell cycle arrest in various cell lines including leukemia (63), liver HepG2 (64), B16 melanoma (65), and prostate LNCaP (66). The antiproliferative effects of resveratrol may be influenced by interactions between dose and duration of exposure. For example, coincident arrest in G1 and downregulation of cyclin D1 were observed at concentrations of 1-5 micromol/L within 24 h, whereas repression of cyclin E and cdk2/4/6, and accumulation of hyperphosphorylated Rb, p53, and p21 were seen at higher doses (10-25 micromol/L) or after longer periods (24-48 h) of exposure (67). At relatively higher doses (10-100

micromol/L) resveratrol was reported to induce accumulation of p27 and repression of signaling through mitogen-activated protein kinase (MAPK)-extracellular signal-regulated kinase (ERK)-1 (MEK-1), ERK1/2, activator protein-1 (AP-1) (68), and nuclear factor kappa beta (NFkappaB) (69). Resveratrol-induced G1-arrest has been also observed in cancer (A431) cells lacking active p53, suggesting it may induce growth arrest through p53-independent activation of p21 (67).

Resveratrol has also been reported to induce S-phase arrest (68-72). In human malignant-B myeloma (73) and ovarian carcinoma Ovar-3 (74) cells, resveratrol induced S-phase arrest and the activation of the ataxia telangiectasia mutated (ATM)/ ataxia telangiectasia and Rad3-related (ATR)/Chk/cdc25c pathway. These effects were indicative of activation by resveratrol of a DNA damage response. For review of the interactions of resveratrol with ATM and ATR please refer to the excellent review by Gatz and Wiesmuller (75). The induction of S-phase arrest has also been documented in a panel of breast cancer cells (MCF-7, MDA-MB-231) following treatment with 10-25 micromol/L resveratrol for 4 d. Biochemical changes that accompanied the growth arrest included inhibition of the phosphatidylinositol 3-kinases (PI3K)/ mammalian target of rapamycin (mTOR)/p70S6L signaling pathway (76).

In HT29 colon cancer cells, resveratrol induced G2 phase arrest, which was accompanied by inactivation of p34/cdc2 protein kinase through inhibition of cdk7 (77). Collectively, these data suggest that resveratrol can affect multiple cell cycle targets depending on the concentration, length of exposure, and type of cell.

The resveratrol analogue pterostilbene has been investigated for its antiproliferative properties. It was shown to inhibit (ED₅₀=4.8 micromol/L) the incidence of DMBA-induced mammary lesions in organ cultures (78), induce cytotoxicity of breast and murine lymphoid cancers (79), and inhibit proliferation of pancreatic (80) and bladder (81) cancers. The administration of pterostilbene to azoxymethane (AOM)-treated F344 rats (15/mg/kg BW pterostilbene, once weekly for 2 wks) or male ICR mice (50 or 250 ppm for 6 or 23 wks) antagonized the formation of aberrant crypt foci (ACF) and iNOS expression (82). The mechanistic actions of pterostilbene against ACF were related to lowered proliferating cell nuclear antigen (PCNA), downregulated expression of beta-catenin and cyclin D1, reduced expression of inflammatory markers (tumor necrosis factor (TNF)alpha, IL-1beta, IL-4, phosphorylated p65) (83), inhibition of rat sarcoma (Ras), PI3K/Akt, and epidermal growth factor (EGF)-receptor (EGFR) signaling (84), and activation of nuclear factor-erythroid2-related factor2 (Nrf2)-mediated antioxidant signaling pathways (85).

In human HT-29 colon cancer cells treated with pterostilbene, the inhibition of cell proliferation was accompanied by reduced expression of proinflammatory iNOS (82). Downregulation of iNOS by pterostilbene (1-20 micromol/L) in macrophages was attributed to inhibition of

NFκB, PI3K/Akt/IKK, and MAPK pathways (86). Pterostilbene reduced the expression of c-Myc and cyclin D1 and was more effective than resveratrol in inhibiting proliferation of HT-29 colon cancer cells (87) and AOM-induced colon tumorigenesis via activation of Nrf2 (85).

3.2.5. Phenolic coumarins and garlic phytoalexins

Psoralidin was documented to inhibit NFκB activation in RAW 264.7 macrophages (88) and androgen-independent prostate PC-3 and DU-145 cancer cells (89). Other studies reported that psoralidin downregulated EGFR-regulated MAPK signaling and inhibited cell proliferation, and that the administration of psoralidin (15 and 25 mg/kg BW) for 5 d/wk for 4 wks suppressed PC-3 (prostate) xenograft tumors in nude mice (90). Therefore, similar to other food phytoalexins, psoralidin may exert anticarcinogenic effects through inhibition of proinflammatory NFκB and MAPK pathways.

Whereas the garlic precursor alliin displayed no antiproliferative properties, its product allicin inhibited the growth of mammary (MCF-7), colon (HT-29), and endometrial (Ishikawa) cells in vitro (91). The growth inhibition of MCF-7 cells was associated with cell cycle arrest in G0/G1 and G2/M. Because allicin is rapidly metabolized, derived compounds including diallyl disulfide (DADS) may contribute to the anti-tumorigenic properties of allicin (24).

These cumulative data clearly suggest that dietary phytoalexins are of interest as anti-proliferative agents. Their cancer preventive effects are likely influenced by concentrations, association with other bioactive compounds, duration of exposure, and cell and tissue-type. The tumor growth inhibitory properties of phytoalexins appear to be related to repression of signaling through PI3K, MAPK, AP-1, and NFκB, and activation of G1, S, and G2 cell cycle checkpoints. The induction of cell cycle arrest by phytoalexins may predispose cells to undergo apoptosis or become more sensitive to other antiproliferative dietary compounds or drugs. For example, certain phytoalexins (i.e. resveratrol) have been shown to function as sensitizers by lowering the threshold response to other anticancer agents (92) or food compounds.

3.3. Apoptosis

3.3.1. Stilbenes

Resveratrol alone or in combination with other therapeutic agents has been reported to induce apoptosis (93, 94). The intrinsic pathway, which is triggered by DNA damage and other types of cellular stress, was induced by resveratrol (50-100 micromol/L) through release of cytochrome-c (Cyt-c) from mitochondria, caspase-3 activation, elevation of Bax, and down-regulation of Mdm2 and the anti-apoptotic B-cell lymphoma-2 (Bcl2) protein. The p53 protein is a component of the intrinsic pathway and it was shown to mediate the proapoptotic effects of resveratrol in human colon (95-96), head and neck squamous (97), breast (98, 99), neuroblastoma (100), and melanoma (65) cancer cells. In addition, resveratrol was reported to stimulate apoptosis through a p53-independent pathway. However, in p53-null cells that had lower

caspase-3 activity, resveratrol did not influence the expression of Bcl-2-associated X protein (Bax) (101).

Resveratrol may also activate the extrinsic pathway through stimulation of the cell surface receptor apoptosis stimulating fragment (Fas) (CD95) and TNF-related apoptosis-inducing ligand (TRAIL)/DR4, and the forkhead transcription factor-1 (FKHRL1) (95). The proapoptotic effects of resveratrol were attributed to inhibition of signaling through PI3K/Akt, prevention of Akt-dependent phosphorylation of forkhead box O (FOXO) transcription factors, reduced binding of 14-3-3 to phosphorylated FOXO, and the subsequent sequestration of FOXO transcription factors to the cytoplasm. Direct transcriptional targets of FOXO include the proapoptotic factors Bim, p27, TRAIL, DR4, and DR5, and the antiapoptotic cyclin D1. The role of FOXO in the resveratrol-induced apoptosis was demonstrated through inhibition of FOXO expression by shRNA, which abrogated resveratrol-induced caspase-3 activity (102). Kinases that phosphorylate FOXO factors (i.e. FOXO4, Thr447 and 451) leading to its activation include reactive oxygen species (ROS)-induced c-Jun N-terminal kinase (JNK) and 5' adenosine monophosphate-activated protein kinase (AMPK) (FOXO3a, and Thr179, 399, 413, 555, 588, and 626) (103). JNK activity was required for resveratrol-induced FasL expression and the subsequent induction of apoptosis in leukemia HL-60 cells (104).

Resveratrol is a known activator of ROS (105) and AMPK (106), which in turn, represses mTOR (107). Because the mTOR pathway is altered in a variety of malignancies, activation of AMPK by resveratrol provides a molecular target in cancer prevention. In prostate cancer PC-3 xenografted tumors, resveratrol stimulated the expressions of TRAIL-R1/DR4, TRAIL-R2/DR5, Bax and p27, and inhibited the expression of Bcl-2 and cyclin D1 (108). Overall, resveratrol may contribute to stimulation of apoptosis through activation of both the intrinsic and extrinsic pathways. Similar proapoptotic effects have been documented for the resveratrol dimer, viniferin (50 micromol/L) in leukemia cells (109).

The resveratrol analogue, pterostilbene, has also been investigated for its proapoptotic properties. In metastatic melanoma SK-MEL cells, it produced caspase 3/7-dependent apoptosis. Combination treatments with pterostilbene plus inositol-6-phosphate produced synergistic growth inhibition (110). Dose-dependent (10-100 micromol/L) induction of apoptosis related to increased caspase activities were observed in lung NCI-H460, SK, MES-1 (111), breast MCF-7 and MDA-MB-231 (112), and pancreatic MIA PaCa-2 (80) cancer cells. In gastric carcinoma AGS cells, the induction of apoptosis via Fas/FasL pathway and caspases-3 was associated with enhanced expression of the growth arrest DNA-damage-inducible (GADD)-45 and GADD-153 genes, and cell cycle arrest in G1. The latter effect was marked by increased expression of the tumor suppressor genes p53, p21, p27, and p16; accumulation of unphosphorylated retinoblastoma (Rb); release of cyt-c in the cytosol; and decreased levels of cyclin A, E, cdk-2, cdk4, and cdk6 (113).

In human bladder cancer cells, pterostilbene induced autophagy through inhibition of PI3K/Akt and the mTOR/p70S6K pathways, and activation of MEK/ERK1/2). These changes preceded apoptosis characterized by cell cycle arrest in G0/G1, reduced levels of cyclins (A, B, D1, and pRb), and induction of caspase-3 activity (81). In HT-29 colon cancer cells, the treatment with pterostilbene increased the levels of cleaved poly (ADP-ribose) polymerase (PARP) (87). Consistent with the induction of proapoptotic responses in cancer cells *in vitro*, pterostilbene was found to induce caspase-3/8/9 activities, PARP cleavage products, and Fas/Fas-L in colonic mucosa of male ICR mice (84). In the model yeast *Saccharomyces cerevisiae* a large number of mitochondrial genes were induced by pterostilbene offering additional mechanistic evidence that apoptosis is a process targeted by this dietary phytoalexin (114).

3.3.2. Phenolic coumarins

Studies reported that psoralidin was cytotoxic against HT-29 (colon), MCF-7 (breast), (115), and SNU (stomach) cancer (116) cell lines. In androgen independent prostate cancer (AIPC) cells (PC-3, DU-145), psoralidin-induced apoptosis was accompanied by downregulation of antiapoptotic Bcl-2, Bcl-xL, and survivin (89). The induction of apoptosis was also accompanied by inhibition of EGF-induced Bcl-2 and survivin, upregulation of Bax and activated caspase-3, and activation of stress-activated protein kinase (SAPK) signaling (90). Interestingly, psoralidin did not cause any toxicity to normal prostate epithelial cells.

In prostate cancer, TNF-mediated signaling is the predominant pathway leading to cell survival and resistance to therapy. In AIPC cells, psoralidin inhibited the constitutive and TNF-induced expression of TNF- α and expression of the prosurvival signaling molecules NF- κ B and Bcl-2 (117). Psoralidin was identified as one of the active compounds isolated from seeds of *Psoralea coryfolia* and believed to be responsible for the inhibition of NO production in LPS-activated macrophages (118).

Proapoptotic effects have been reported for the coumarin-related phytoalexin scopoletin (6-methoxy-7-hydroxycoumarin), which has been isolated from *Erycibe obtusifolia*, *Artemisia Montana*, and *Gelsemium sempervirens*. In HL-60 promyelocytic cells, scopoletin induced apoptosis accompanied by activation of caspase-3, cleavage of PARP, and DNA fragmentation (119). In AHH-1 TK^{+/−} human lymphoblastoid cells, exposure to coumestrol dose-dependently (10–50 micromol/L) induced a significant increase in micronuclei. The highest frequency of micronuclei occurred 2 d after exposure to coumestrol and decreased afterwards. Parallel to the decrease in the micronucleus frequency, coumestrol increased the percentage of cells undergoing apoptosis (120).

3.3.3. Glycoalkaloids

The potato phytoalexins alpha-chaconine and alpha-solanine were reported to induce apoptotic cell death of HT-29 human colon cancer cells. However, alpha-chaconine was more potent than alpha-solanine, and it induced apoptosis through caspase-3 activation and

inhibition of ERK 1/2 phosphorylation (18). Similar effects by alpha-chaconine were documented in LNCaP cells through induction of PARP cleavage and activation of JNK, and this response played a major role in the induction by alpha-chaconine of caspase-dependent apoptosis (121). These results suggest that apoptosis induced by whole potato extracts in prostate cancer cell lines may be in part due to alpha-chaconine (122).

3.3.4. Garlic phytoalexins

Allicin is a garlic thiosulfinate known to induce apoptosis through both extrinsic and intrinsic pathways. In cancer cells, it induced cyt-c release from the mitochondria, increased caspase-3, -8, and -9 activities, and upregulated the expression of Bax and Fas (123-124). Similar proapoptotic effects were observed in colon cancer HCT-116 (125) and promyelocytic-leukemia HL-60 (126) cells in which allicin decreased the Bcl-2/Bax ratio, while stimulating the mitochondrial release of cyt-c and activation of caspase 3/9. Interestingly, the proapoptotic properties of allicin have been exploited for the development of site-directed apoptotic killing. Using a rituximab monoclonal CDC20 antibody-aliinase conjugate, upon addition of aliin, allicin was formed *in situ*, killing CD20+ tumor B-chronic lymphocytic leukemia cells via apoptosis. Following treatment with aliin for 72 h, an 85% reduction was observed in the number of viable cells. The *in situ* generation of allicin in cells was also proposed as a strategy to overcome the known problem of the short-lived allicin molecules in the circulation (127).

3.3.5. Di-terpenes

One of the conditions that characterize solid tumor growth is hypoxia which makes tumors less responsive to therapy. Studies with the phytoalexin and di-terpene momilactone-B found in rice (*Oryza sativa* L.) hulls documented this food component suppressed hypoxia-induced cyclin D1, cdk4, hypophosphorylated Rb, and Bcl-2 levels, whereas it increased the cellular content of proapoptotic Bax and caspase-3 protein (128). Anticarcinogenic effects of momilactone B were also documented in human lymphoma cells (Jurkat) through elevation of PARP, caspase-3, cytosolic cyt-c, and reduced phosphorylated Bad (129), and in colon cancer HT-29 and SW620 cells through reduced survival (130). Overall, these studies suggest phytoalexin compounds can impact mitochondrial functions and death receptors distribution leading to activation of cell-death complexes characteristic of apoptosis.

3.4. Invasion and metastasis

Tumor cell invasion is a key event in the metastatic process. It includes attachment of tumor cells to extracellular proteins through tumor-cell receptors and degradation of extracellular matrix (ECM) components via proteinases such as matrix metalloproteinase (MMP), of which four subclasses have been characterized: collagenase, gelatinase, stromelysin, and membrane-associated MMP. The breakdown of the extracellular matrix is followed by penetration through the basement membrane of capillary and lymphatic vessels, intravasation, and growth in new tissue (reviewed in 131).

3.4.1. Glycoalkaloids

A phytoalexin with anti-invasion and anti-metastatic properties is alpha-solanine. At concentrations ranging from 5 to 20 micromol/L, it was reported to inhibit human melanoma A2058 cells migration and invasion by reducing MMP-2 (gelatinase-A) and MMP-9 (gelatinase-B) activities. The MMP-2 and MMP-9 are known to play a key role in the process of metastasis. The expression of MMP-9 is stimulated by TNFalpha, vascular endothelial growth factor (VEGF), EGF, transforming growth factor (TGF)beta, and Ras through various signaling pathways. Transcription factors that activate MMP-9 include AP-1 and NFkappaB, which are activated through MAPK and PI3K pathways. In A2058 cells, alpha-solanine inhibited the phosphorylation of JNK, PI3K, and Akt, and reduced the levels of nuclear NFkappaB (132). Similar antimetastatic effects were reported for a related potato phytoalexin, alpha-chaconine, which inhibited MMP-2/9 activities and suppressed JNK and PI3K/Akt/NFkappaB signaling pathways in human lung adenocarcinoma A549 cells (133), and tube formation of bovine aortic endothelial (BAEC) cells (134).

3.4.2. Garlic phytoalexins

Anti-invasion and -metastatic mechanisms of action have been documented for allicin, which in human endothelial cells antagonized gamma-radiation-induced JNK/AP-1 activity and reduced the expression of the downstream target intercellular adhesion molecule-1 (ICAM-1/CD54). The ICAM-1 is an inducible surface glycoprotein that facilitates adhesion-dependent cell-to-cell interactions and invasion of cells through the ECM (135). Therefore, by reducing ICAM-1 levels allicin may contribute to reducing invasion.

3.4.3. Stilbenes

In rodent models, the treatment with resveratrol reduced angiogenesis, VEGF and VEGF receptor-2 (VEGFR2)-positive cells, and markers of metastasis (MMP-2 and MMP-9) (108). Similar repressive effects on MAPK, PI3K/Akt, NFkappaB, and AP-1 pathways leading to MMP-9, and reduced invasion and metastasis were reported for pterostilbene in liver HepG2 (136) and breast cancer MCF-7 cells activated with heregulin-beta1, a ligand of human EGFR-2 (HER-2) (137). The blockage of heregulin functions is known to inhibit tumorigenesis and metastasis of breast cancer cells (138). Repressive effects on heregulin-beta1-mediated MMP-9 expression and cell invasion have been also reported for resveratrol in human breast cancer cells (139).

3.4.4. Phenolic coumarins

The potential for preventing invasion has been documented by investigations with the phytoalexin coumestrol, which inhibited (2.5 to 10 micromol/L) cell invasion of MDA-MB-231 breast cancer cells in matrigel invasion assays (140), and reduced intercellular adhesion and migration in vivo (141). In human umbilical vein endothelial cells, scopoletin inhibited VEGF-induced tube formation, proliferation and migration. These effects were associated with inhibition of VEGF-induced autophosphorylation of VEGFR2, and downregulation of ERK1/2 and p38 MAPK activities (142). Overall, the multiple targeting by dietary phytoalexins of MAPK,

PI3K/Akt, NFkappaB, and AP-1 pathways leading to activation of factors involved in the breakdown of ECM components and invasion highlights the potential use of these compounds in the prevention of the metastatic process.

3.5. Hormonal regulation

3.5.1. Soy phytoalexins

The intake of soy food components has been linked to reduced risk of endocrine tumors. The inhibition of estrogen binding to estrogen receptor (ER) by the soy phytoalexin glyceollin occurs at low micromolar concentration and it is 3-fold higher for the ERalpha (IC₅₀ about 6 micromol/L compared to ERbeta (IC₅₀ of about 16 micromol/L) (143). Compared to genistein and daidzein, glyceollins are stronger inhibitors of ER signaling in breast cancer cells (144), and suppress estrogen-dependent breast and ovarian tumorigenesis in ovariectomized athymic mice (145). In contrast to tamoxifen, glyceollins do not exhibit agonistic effects on uterine morphology and antagonize the uterotrophic stimulation of estrogen. The absence of uterotrophic activity is characteristic of pure antiestrogens (146) and it is of particular interest for glyceollins since antiestrogen therapies based on tamoxifen have been shown to increase the risk of endometrial cancers (147).

The intraperitoneal treatment of nu/nu immune-compromised ovariectomized mice with 20 mg/kg/d for 15 d of a glyceollin mixture reduced estrogen-induced mammary tumor formation. In postmenopausal female monkeys, the supplementation with glyceollins (134 mg/d) prevented the estradiol-dependent stimulation of mammary proliferation. Also, glyceollin increased the expression of ERalpha while reducing the expression of the progesterone receptor (PR) and trefoil factor-1 (TFF1) (148). The dose of 134 mg/d used in the latter study is theoretically achievable in humans through diet but it is considerably higher than the typical dietary isoflavone consumption observed in Western populations (lower than 5 mg/d) and the one reported (about 60 mg/d) for some Asian diets (149). Glyceollin-enriched soy products have been suggested as a strategy to increase the intake of glyceollins and ameliorate the estrogenic effects of soy isoflavones. For example, soy yogurt produced from black soybeans (*Glycine max* L. Merrill) after fungal stress with food-grade *Rhizopus oligosporus* was enriched (1 mg/g) in total glyceollins and had reduced levels of undesirable oligosaccharides stachyose and raffinose (150).

In contrast to glyceollins, glycinol, a precursor of glyceollins, exhibited potent estrogenic activities including stimulation of proliferation of breast cancer cells, expression of PR, and transactivation at estrogen response elements (ERE). Because the production of glyceollins is influenced by the type and duration of stress (i.e. fermentation process), the cancer preventative effects of soy-based foods may be influenced by the relative content of glycinol and glyceollins (151). These observations suggest caution should be exercised when recommending the use of soy-derived products for cancer prevention.

Studies with androgen-responsive human prostate (LNCaP) cancer cells documented that a mixture of glyceollins (I=68%, II=21%, III=11%) had growth

inhibitory properties. The glyceollin mixture inhibited growth of LNCaP cells in a dose-dependent fashion (0.25 to 25 micromol/L). These effects were due to inhibition of G1/S progression and correlated with upregulation of cdk inhibitor 1A and 1B. In addition, glyceollin at concentrations ranging from 0.25 to 12.5 micromol/L inhibited estrogen-, but not dihydrotestosterone (DHT)-induced growth and prostate-specific antigen (PSA) expression in LNCaP cells. Furthermore, the glyceollin mixture reduced the expression of the androgen/estrogen-responsive genes NKX3.1 and insulin-like growth factor-1 receptor (IGF-1R). Intraperitoneal treatment of nu/nu immune-compromised ovariectomized mice with 20 mg/kg/d for 15 d of glyceollin mixture reduced estrogen-induced mammary tumor growth derived from xenografted MCF-7 cells injected into the mammary fat pad (152).

The inhibition of cell proliferation by glyceollin mixtures has been attributed to antagonistic actions on the ERalpha by the (-)-glyceollin-I isoform in the cis (6aS, 11aS) configuration. In ER competition studies, this isomer had the highest affinity for the ERalpha with displacement of 50% estradiol bound to ERalpha at a concentration of about 2.0 nanomol/L. It also had antagonistic actions on proliferation of MCF-7 and ovarian (BG-1) cancer cells similar to those observed for 4-OH-tamoxifen and ICI 182,780 (153). Compared to other glyceollin isoforms, the stronger antiestrogenic effects of (-)-glyceollin-I were attributed to substitutions at the A ring. The (-)-glyceollin I isomer was documented to decrease the transcriptional activity of ER and downregulate the expression of the PR (154).

In vitro, glyceollin I, but not glyceollin II and III showed significant inhibition of ERE activation suggesting this isomer is primarily responsible for the antiestrogenic properties of soy-derived glyceollins (155). Overall, these studies suggest glyceollins have unique ER-modulator properties without agonist activity.

3.5.2. Phenolic coumarins

Compared to glyceollins, the soy phytoalexin coumestrol competes with estrogen for binding to ER at lower, nanomolar, levels and its binding affinity for ERbeta (IC₅₀= 35 nanomol/L) is higher compared to that of the ERalpha IC₅₀=109 nanomol/L). Coumestrol has been investigated as a potential alternative to hormone replacement therapies (156). However, both estrogenic and antiestrogenic effects have been reported for coumestrol. At low estrogen levels (0.01 nanomol/L), coumestrol (less than 10 micromol/L) acted as an estrogen and stimulated cell growth of ER-positive breast cancer cells. Conversely, at higher estrogen levels (1 nanomol/L) coumestrol (10 micromol/L) inhibited cell proliferation (157). The administration of coumestrol (60 mg/kg/d) to immature intact rats stimulated uterine hyperplasia (158) suggesting coumestrol-rich diets may actually induce uterus growth during conditions of low estrogen exposure (i.e. prepuberty, postmenopause). These effects were not in agreement with those of other reports documenting dietary coumestrol reduced the burden of colon tumorigenesis in the Apc Min/+ mouse model. The anticarcinogenic actions of coumestrol may be due to restoration of E-cadherin-beta-

catenin interactions, which are usually observed following treatment with chemopreventive drugs such as sulindac (141).

Although studies of coumestrol consumption reported very low dietary exposure to this phytoalexin compared to other phytoestrogens (i.e. genistein) (159-160), coumestrol has been shown to have higher binding affinity for ERalpha (IC₅₀=21 nanomol/L) and ERbeta (9 nanomol/L) compared to genistein (520 and 16 nanomol/L) and resveratrol (1 and 0.7 micromol/L) (161). Therefore, timing of exposure, tissue-type, and doses relative to endogenous estrogen concentrations may be important determinants of the effects of coumestrol on cancer risk. In support of this concept, case-control studies that examined the relationship between dietary intake of coumestrol and testicular cancer risk reported a multivariate U-shaped relationship with increased cancer risk at low (less than 19 microg) and high (more than 84 microg) levels of dietary coumestrol/1,000 kcal (162). An inverse relationship between daily intake of coumestrol and prostate cancer risk (OR=0.48) was also observed in a case-control study in Caucasian subjects (163) with median intake levels of coumestrol of 67.5 and 45 microg/d, respectively in control and case subjects. The latter studies further highlight the impact of levels of coumestrol intake on cancer risk.

3.5.3. Bean phytoalexins

In binding assays, kievitone had higher affinity and increased ERE transcriptional activity for ERalpha, whereas phaseollin had higher affinity and increased transcriptional activity for ERbeta. However, concentrations of 0.1 micromol/L kievitone and phaseollin had respectively only 10% and 2% the estrogenic activity for ERalpha compared to equimolar concentrations of genistein. Both kievitone and phaseollin at the concentration of 10 micromol/L reduced by about 50% the MCF-7 colony formation induced by estrogen (29). Kievitone inhibited proliferation of MCF-7 cells stimulated with estrogen (IC₅₀=5-18 micromol/L) and various growth factors (IGF-1, IGF-2, TGF; IC₅₀=1-3 micromol/L) (164). Therefore, kievitone may inhibit signaling components that are common to growth factor pathways. These results suggest legume phytoalexins possess antiestrogenic activity and may hold potential for cancer prevention in estrogen-responsive tissue.

3.5.4. Arylbenzofurans

The treatment with the arylbenzofuran compound ebenfuran-III isolated from *Onobrychis ebenoides* (Leguminosae) was reported to inhibit proliferation of MCF-7 cells at concentrations of 1 micromol/L while inducing G1 phase arrest. It also suppressed estradiol-induced Bcl2 expression in MCF-7 cells and induced apoptotic death (165). Other studies revealed that ebenfuran II exhibited antiestrogenic activity in breast cancer cells via the ER, with no stimulatory effects on cervix adenocarcinoma cells (31). These studies suggest that plant arylbenzofuran phytoalexins may be useful for the prevention of breast cancer.

3.5.5. Stilbenes

The effects of resveratrol in breast tissue have been investigated based on early evidence it exerted agonistic effects on the ER (166). It binds to ER α and ER β with comparable affinity, which however, is about 7,000-fold lower compared to that of estradiol (167). Resveratrol significantly reduced the Bcl-2/Bax ratio in ER-positive MCF-7 breast cancer cells. This effect, however, was abolished by ER α silencing. Because estrogen is a known activator of Bcl-2, resveratrol may induce apoptosis in the absence of apoptosis-inducing stimuli, at least in part via inhibition of ER α functions in breast cancer cells (168). Resveratrol is also a ligand of the aromatic hydrocarbon receptor (AhR), which physically binds the ER α . It was reported to reverse AhR-induced DNA adducts formation (169) and repression of BRCA-1 in breast cancer cells (170). The binding of resveratrol to nuclear receptors has been proposed to induce changes in receptor-complexes conformation altering interactions with cofactors and DNA at promoter elements. This inhibitory mechanism of resveratrol on transcriptional activity has been suggested for the androgen receptor (AR) at androgen response elements (171), the AhR at xenobiotic response elements (XRE) (172), and the ER at ERE (167). Consistent with these mechanisms, resveratrol was shown to inhibit estradiol and androgen-induced proliferation of AR-positive LNCaP cells *in vitro* (173). Collectively, these studies suggest that phytoalexin-rich diets may be useful in the prevention of endocrine-related tumors.

3.6. Modulation of phase-I/II metabolizing enzymes activities

Whereas the ideal balance between Phase I and phase II enzymes for cancer prevention remains elusive, protective effects of phytoalexins have been related to inhibition of Phase I bioactivating and/or induction of Phase II detoxifying enzymes. One transcription factor that induces Phase II metabolizing activities is Nrf2, which binds to antioxidant response elements (ARE) harbored in the promoter region of genes coding for detoxifying enzymes. Nrf2 is activated and translocated from the cytosol to the nucleus under conditions of exposure to xenobiotics and oxidative stress (174-175). Phase I enzymes are induced by the AhR at XRE. Crosstalk between Nrf2 and the AhR has been proposed since the AhR activates the transcription of Nrf2 and Phase I (i.e. CYP) and Phase II enzymes such as quinone reductase (QR), glutathione-S-transferase (GST), and uridine 5'-diphospho-glucuronosyltransferase (UGT) genes at XRE (176).

The activation of Nrf2 activity was proposed to mediate the anticarcinogenic properties of brassinin and cyclobraassinin, which inhibited DMBA-induced mammary lesions in organ culture through induction of QR, also known as NAD(P)H:quinine oxidoreductase (NQO1) (54). The QR is one among many of the antioxidant response element (ARE)-dependent genes regulated by Nrf2 (177). Similarly, the phenolic coumarin psoralidin isolated from an ethyl acetate-soluble fraction of *Psoralea coryfolia* and coumestrol were reported to induce QR activity in Hepa 1c1c7 murine hepatoma (178) and colonic Colo205 (157)

cells. Also, siRNA studies with HCT116 colon cancer cells documented that the garlic phytoalexin allicin stimulated the translocation of Nrf2 to the nucleus. (125). A role for allicin in protecting against oxidative stress has been suggested by other studies documenting activation of cellular glutathione (GSH) levels in vascular endothelial cells (179), possibly through upregulation of the phase II enzyme glutamate-cysteine-ligase modifier (GCLM), which is the rate limiting enzyme for de-novo glutathione biosynthesis (180).

An alternative mechanism of protection by phytoalexins is related to inhibition of Phase I enzymes that participate in the bioactivation of carcinogens. For example, protective effects of increasing levels of alliin in garlic powder (5%) in the diet were reported in rat liver and colon tissue through inhibition of DNA damage induced with N-nitrosodimethylamine (NDMA), 1,2-dimethylhydrazine (DMH), methylmethane sulfonate (MMS), and aflatoxin B1 (AFB1). The alliin-dependent decrease in DNA damage was attributed at least in part to reduced activity of CYP enzymes, which participate in activation of these carcinogens (181-182).

The anticarcinogenic effects of the phytoalexin resveratrol have also been related at least in part to its repressive effects on expression of CYP enzymes (183-185) through inhibition of the AhR (186) and activation of Phase II enzymes (i.e. QR1) (187-188). However, resveratrol had minimal effects on levels of Phase II enzymes in a rodent (CD1) model (20 or 50 mg/kg BW) (189) and significant effects (1 g resveratrol/d for 4 wks) only in humans subjects with low baseline activity (GST-pi, UGT1A1) (190). The lack of strong induction of Phase II enzymes is somewhat in contrast with the reported stimulatory effects of resveratrol on Nrf2 activation (191) and prevention of diethylnitrosamine-induced liver tumorigenesis (192).

3.7. Bioavailability of phytoalexins

Although many prevention studies have focused on the anticancer effects of sulforaphane (SFN), recent investigations have reported conflicting data about its natural phytoalexin precursor 4-methylsulphinylbutyl glucosinolate also known as glucoraphanin (GRP). GRP is consumed in diets containing cruciferous vegetables. In human liver carcinoma HepG2 cells, GRP was shown to induce Nrf2 translocation and QR activity (193). However, in a rodent model, the repeated administration of GRP led to significant induction of hepatic Phase I enzymes including CYP1A1/2, CYP3A1/2, and CYP2E1 with only modest activation of GST (194). Activation of CYP enzymes by GRP (1 micromol/L) has been confirmed by more recent studies (195). These investigations raise the possibility that the consumption of cruciferous varieties containing or engineered to produce higher levels of GRP may actually promote deleterious health effects through activation of Phase I enzymes. Moreover, conditions that alter bioavailability of phytoalexins (i.e. GRP, resveratrol) through higher intake or deactivation of modifying enzymes (i.e. myrosinase activity for GRP) may interfere with metabolizing activities, and consequently, influence

cancer risk. For example, modulation of metabolism or competition by other dietary agents for the same Phase II enzymes may actually increase the concentration of parent resveratrol (196) or increase its cancer protective effects (85). Likewise, several studies provide evidence that allyl sulfur compounds can induce GST activity and thereby enhance removal of foreign compounds, which may otherwise induce cancer (197).

The content of phytoalexins in plant tissues depends on the plant species, cultivar, agricultural practices, and stage of maturity. One important question related to the cancer prevention effects of phytoalexins is whether they reach and accumulate in human target tissue at concentrations that mimic those tested in vitro and animal studies. For example, most in vitro studies that have investigated the effects of resveratrol have used concentrations ranging from 10 to 50 micromol/L. However, plasma concentrations of resveratrol in humans were reported to reach maximal levels of about 2.4 micromol/L following supplementation with a single dose (5 g) of resveratrol (198). Clinical studies suggested that target plasma concentrations of resveratrol should not surpass 1 micromol/L through the intake of 1g/d or less (199). However, only a few preclinical studies have adopted this micromolar range (Table 2) complicating the interpretation of resveratrol data from in vitro studies. Similar concerns persist about the concentrations of other phytoalexins used in preclinical studies.

4. SUMMARY AND PERSPECTIVE

Phytoalexins exert pleiotropic effects against cancer via inhibition of microbial activity, cell proliferation, invasion, and metastasis. They can also influence hormonal regulation and drug detoxification mechanisms. Moreover, phytoalexins regulate the expression of many metabolizing enzymes that may alter multiple pathways in normal and cancerous cells. Although opportunities exist for the development of cancer prevention strategies based on dietary phytoalexins, future research should address whether concentrations and regimens that show efficacy in preclinical studies are attainable in humans. Also, knowledge gaps persist about tissue-specific effects and differential responses in normal vs cancer cells. Future research focusing on interactions of phytoalexins with other food components and additive effects of combinations of phytoalexins on cancer processes may help in developing cancer prevention regimens that are nutritionally relevant while alleviating potential problems associated with the supplemental use of supraphysiological doses.

5. ACKNOWLEDGMENTS

This work was supported by an IPA from the National Cancer Institute, National Institutes of Health, Bethesda, MD, to Donato F. Romagnolo.

6. REFERENCES

1. Stephen Boue, Thomas Cleveland, Carol Carter-Wientjes, Betty Shih, Deepak Bhatnagar, John McLachlan,

and Matthew Burow: Phytoalexin-enriched functional foods. *J Agric Food Chem* 57, 2614-2622 (2009)

2. Hans VanEtten, John Mansfield, John Bailey, and Edward Farmer: Two Classes of Plant Antibiotics: Phytoalexins versus "Phytoanticipins" *Plant Cell*. 9,1191-1192 (1994)

3. Marina Naoumkina, Mohamed Farag, Lloyd Sumner, Yuhong Tang, Chang-Jun Liu, and Richard Dixon: Different mechanisms for phytoalexin induction by pathogen and wound signals in *Medicago truncatula*. *Proc Natl Acad Sci USA* 104, 17909-17915 (2007)

4. Roman Mezencev, Peter Kutschy, Aneta Salayova, Taylor Updegrave, and John McDonald: The design, synthesis and anticancer activity of new nitrogen mustard derivatives of natural indole phytoalexin 1-methoxyspirobrassinol. *Neoplasma* 56, 321-330 (2009)

5. Shozo Kobayashi, Chang-Kui Ding, Yasuhiro Nakamura, Ikuko Nakajima, and Ryoji Matsumoto: Kiwifruits (*Actinidia deliciosa*) transformed with a *Vitis* stilbene synthase gene produce piceid (resveratrol-glucoside). *Plant Cell Rep* 19, 904-910 (2000)

6. Susanne Rühmann, Dieter Treutter, Steffi Fritsche, Karlis Briviba, and Iris Szankowski: Piceid (resveratrol glucoside) synthesis in stilbene synthase transgenic apple fruit. *J Agric Food Chem* 54, 4633-4640. (2006)

7. Giovanna Giovinazzo, Leone D'Amico, Annalisa Paradiso, Roberto Bollini, Francesca Sparvoli, and Laura DeGara: Antioxidant metabolite profiles in tomato fruit constitutively expressing the grapevine stilbene synthase gene. *Plant Biotechnol J* 31, 57-69 (2005)

8. John Hipkind and Nancy Paiva: Constitutive accumulation of a resveratrol-glucoside in transgenic alfalfa increases resistance to *Phoma medicaginis*. *Mol Plant Microbe Interact* 13, 551-562 (2000)

9. Kevin Holland and Sean O'Keefe: Recent applications of peanut phytoalexins. *Recent Pat Food Nutr Agric* 2, 221-232 (2010)

10. Bettina Deavours and Richard Dixon: Metabolic engineering of isoflavonoid biosynthesis in alfalfa. *Plant Physiol* 138, 2245-2259 (2005)

11. Soledade Pedras and Estifanos Yaya: Phytoalexins from Brassicaceae: news from the front. *Phytochemistry* 71, 1191-1197 (2010)

12. Mendel Friedman and Carol Levin: alpha-Tomatine content in tomato and tomato products determined by HPLC with pulsed amperometric detection. *J Agric Food Chem* 43, 1507-1511 (1995)

13. Jun Ning, Fanzuo Kong, Bangmao Lin, and Huide Lei: Large-scale preparation of the phytoalexin elicitor

- glucohexatose and its application as a green pesticide. *J Agric Food Chem* 51, 987-991 (2003)
14. Otto Daniel, Mattias Meier, Josef Schlatter, and Peter Frischknecht: Selected phenolic compounds in cultivated plants: ecologic functions, health implications, and modulation by pesticides. *Environ Health Perspect.* 107, 109-14 (1999)
15. Soledade Pedras, Denis Okinyo-Owiti, Ken Thoms, and Adewale Adio: The biosynthetic pathway of crucifer phytoalexins and phytoanticipins: de novo incorporation of deuterated tryptophans and quasi-natural compounds. *Phytochemistry* 70, 1129-1138 (2009)
16. Farag Ibraheem, Iffa Gaffoor, and Surinder Chopra: Flavonoid phytoalexin-dependent resistance to anthracnose leaf blight requires a functional yellow seed1 in Sorghum bicolor. *Genetics* 70, 1129-1138 (2010)
17. Phillip Wharton and Ralph Nicholson: Temporal synthesis and radiolabelling of the sorghum 3-deoxyanthocyanidin phytoalexins and the anthocyanin, cyanidin 3-dimalonyl glucoside. *New Phytologist* 145, 457-469 (2000)
18. Seun Yang, Seung-Hwan Paek, Nobuyuki Kozukue, Kap-Rang Lee, and Jung-Ae Kim: Alpha-chaconine, a potato glycoalkaloid, induces apoptosis of HT-29 human colon cancer cells through caspase-3 activation and inhibition of ERK 1/2 phosphorylation. *Food Chem Toxicol* 44, 839-846 (2006)
19. Sinead Milner, Nigel Brunton, Peter Jones, Nora O' Brien, Stuart Collins, and Anita Maguire: Bioactivities of glycoalkaloids and their aglycones from solanum species. *J Agric Food Chem* 59, 3454-3484 (2011)
20. Kathryn Roupe, Connie Remsberg, Jamie Yáñez, and Neal Davies: Pharmacometrics of stilbenes: segueing towards the clinic. *Curr Clin Pharmacol* 1, 81-101 (2006)
21. Tao Shen, Xiao-Ning Wang, and Hong-Xiang Lou: Natural stilbenes: an overview. *Nat Prod Rep.* 26, 916-935. (2009)
22. Luigi Bavaresco: Role of viticultural factors on stilbene concentrations of grapes and wine. *Drugs Exp Clin Res* 29, 181-187 (2003)
23. Naznin Khatune, Ekramul Islam, Ekramul Haque, Proma Khondkar, and Mukhlesur Rahman: Antibacterial compounds from the seeds of *Psoralea corylifolia*. *Fitoterapia* 75, 228-230 (2004)
24. Kun Song and John Milner: The influence of heating on the anticancer properties of garlic. *J Nutr* 131, 1054S-1057S (2001)
25. Tomonobu Toyomasu, Takuma Kagahara, Kazunori Okada, Jinichiro Koga, Morifumi Hasegawa, Wataru Mitsuhashi, Takeshi Sassa, and Hisakazu Yamane: Diterpene phytoalexins are biosynthesized in and exuded from the roots of rice seedlings. *Biosci Biotechnol Biochem* 72, 562-567 (2008)
26. Stephen Boue, Carol Carter, Kenneth Ehrlich, and Thomas Cleveland: Induction of the soybean phytoalexins coumestrol and glyceollin by *Aspergillus*. *J Agric Food Chem* 48, 2167-2172 (2000)
27. Luzia Modolo, Fernando Cunha, Marcia Braga, and Ione Salgado: Nitric oxide synthase-mediated phytoalexin accumulation in soybean cotyledons in response to the *Diaporthe phaseolorum* f. sp. meridionalis elicitor. *Plant Physiol* 130, 1288-1297 (2002)
28. Serena Landini, Madge Graham, and Terrence Graham: Lactofen induces isoflavone accumulation and glyceollin elicitation competency in soybean. *Phytochemistry* 62, 865-874 (2003)
29. Stephen Boue, Matthew Burow, Thomas Wiese, Betty Shih, Steven Elliott, Carol Carter-Wientjes, John McLachlan, and Deepak Bhatnagar: Estrogenic and antiestrogenic activities of phytoalexins from red kidney bean (*Phaseolus vulgaris* L.). *J Agric Food Chem* 59, 112-120 (2011)
30. Yan Yang, Ting Gong, Chao Liu, and Ruo-Yun Chen: Four new 2-arylbenzofuran derivatives from leaves of *Morus alba* L. *Chem Pharm Bull* 58, 257-260 (2010)
31. Zoi Papoutsis, Eva Kassi, Dimitra Papaevangelou, Harris Pratsinis, Vassilis Zoumpourlis, Maria Halabalaki, Sofia Mitakou, Anastasios Kalofoutis, and Paraskevi Moutsatsou: Plant 2-arylbenzofurans demonstrate a selective estrogen receptor modulator profile. *Steroids* 69, 727-734 (2004)
32. David Schottenfeld and Jennifer Beebe-Dimmer: Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. *CA Cancer J Clin* 56, 69-83 (2006)
33. Sebastian Suerbaum and Pierre Michetti: *Helicobacter pylori* infection: *N Engl J Med* 347, 1175-1186 (2002)
34. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans: Schistosomes, liver flukes and *Helicobacter pylori*. In: *IARC Monogr Eval Carcinog Risks Hum.* 61, 1-241 (1994)
35. James Scheiman and Alan Cutler: *Helicobacter pylori* and gastric cancer. *Am J Med* 106, 222-226 (1999)
36. Bettina Breuer-Katschinski, Kurt Nemes, Amy Marr, Bjorn Rump, Barbel Leiendecker, Norbert Breuer, and Harald Goebell: *Helicobacter pylori* and the risk of colonic adenomas. Colorectal Adenoma Study Group. *Digestion* 60, 210-215 (1999)
37. Stefano Censini, Christina Lange, Zhaoying Xiang, Jean Crabtree, Paolo Ghiara, Mark Borodovsky, Rino

- Rappuoli, and Antonello Covacci: cag, a pathogenicity island of *Helicobacter pylori*, encodes type I-specific and disease-associated virulence factors. *Proc Natl Acad Sci USA* 93, 14648-14653 (1996)
38. Gail Mahady and Susan Pendland: Resveratrol inhibits the growth of *Helicobacter pylori* in vitro. *Am J Gastroentero* 95,1849 (2000)
39. Yogeeshwer Shukla and Richa Singh: Resveratrol and cellular mechanisms of cancer prevention. *Ann N Y Acad Sci* 1215, 1-8 (2011)
40. Gail Mahady, Susan Pendland, and Lucas Chadwick: Resveratrol and red wine extracts inhibit the growth of CagA+ strains of *Helicobacter pylori* in vitro. *Am J Gastroenterol* 98, 1440-1441 (2003)
41. Syed Zaidi, Kanwal Ahmed, Takeshi Yamamoto, Takashi Kondo, Khan Usmanghani, Makoto Kadowaki, and Toshiro Sugiyama: Effect of resveratrol on *Helicobacter pylori*-induced interleukin-8 secretion, reactive oxygen species generation and morphological changes in human gastric epithelial cells. *Biol Pharm Bull* 32, 1931-1935 (2009)
42. Jean Crabtree, Antonello Covacci, Susan Farmery, Zhaoying Xiang, David Tompkins, Sarah Perry, Ivan Lindley, Rino Rappuoli: *Helicobacter pylori* induced interleukin-8 expression in gastric epithelial cells is associated with CagA positive phenotype. *J Clin Pathol* 48, 41-45 (1995)
43. Paolo Ruggiero, Giacomo Rossi, Francesco Tombola, Laura Pancotto, Laura Lauretti, Giuseppe Del Giudice, and Mario Zoratti: Red wine and green tea reduce H pylori- or VacA-induced gastritis in a mouse model. *World J Gastroenterol* 13, 349-354 (2007)
44. Liam Murray, Athene Lane, Ian Harvey, Jenny Donovan, Prakash Nair, and Richard Harvey: Inverse relationship between alcohol consumption and active *Helicobacter pylori* infection: the Bristol *Helicobacter* project. *Am J Gastroenterol* 97, 2750-2755 (2002)
45. Steffen Rosenstock, Torben Jorgensen, Lief Andersen, and Olaf Bonnevie: Association of *Helicobacter pylori* infection with lifestyle, chronic disease, body-indices, and age at menarche in Danish adults. *Scand J Public Health* 28, 32-40 (2000)
46. K.T. Augusti. Therapeutic values of onion (*Allium cepa* L.) and garlic (*Allium sativum* L.). *Indian J Exp Biol* 34, 634-640 (1996)
47. Pablo Canizares, Ignacio Gracia, Luis Gómez, Carlos Martín de Argila, Daniel Boixeda, Antonio García, and Luis de Rafael: Allyl-thiosulfonates, the bacteriostatic compounds of garlic against *Helicobacter pylori*. *Biotechnol Prog* 20, 397-401 (2004)
48. Jinkun Shen, Larry Davis, Judy Wallace, Yen Cai, and Larry Lawson: Enhanced diallyl trisulfide has in vitro synergy with amphotericin B against *Cryptococcus neoformans*. *Planta Med* 62, 415-418. (1996)
49. Shuang Liu, Yundong Sun, Wenjuan Li, Han Yu, Xi Li, Zhifang Liu, Jiping Zeng, Yabin Zhou, Chunyan Chen, and Jihui Jia: The antibacterial mode of action of allitridi for its potential use as a therapeutic agent against *Helicobacter pylori* infection. *FEMS Microbiol Lett* 303, 183-189 (2010)
50. Masaki Imuro, Hideyuki Shibata, Toshihiko Kawamori, Takayuki Matsumoto, Tetsuo Arakawa, Takashi Sugimura, and Keiji Wakabayashi: Suppressive effects of garlic extract on *Helicobacter pylori*-induced gastritis in Mongolian gerbils. *Cancer Lett* 187, 61-68 (2002)
51. Mitchell Gail and Wei-Cheng You: A factorial trial including garlic supplements assesses effect in reducing precancerous gastric lesions. *J Nutr* 136, 813S-815S (2006)
52. Johan Billing and Paul Sherman: Antimicrobial functions of spices: why some like it hot. *Q Rev Biol* 73, 3-49 (1998)
53. Rajendra Mehta, Jinfang Liu, Andreas Constantinou, Cathy Thomas, Michael Hawthorne, Min You, Clarissa Gerhäuser, John Pezzuto, Richard Moon, and Robert Moriarty: Cancer chemopreventive activity of brassinin, a phytoalexin from cabbage. *Carcinogenesis* 16, 399-404 (1995)
54. Rajendra Mehta, Jinfang Liu, Andreas Constantinou, Michael Hawthorne, John Pezzuto, Richard Moon, and Robert Moriarty: Structure-activity relationships of brassinin in preventing the development of carcinogen-induced mammary lesions in organ culture. *Anticancer Res* 14, 1209-1213 (1994)
55. Clarissa Gerhäuser, Min You, Jinfang Liu, Robert Moriarty, Michael Hawthorne, Rajendra Mehta, Richard Moon, and John Pezzuto: Cancer chemopreventive potential of sulforamate, a novel analogue of sulforaphane that induces phase 2 drug-metabolizing enzymes. *Cancer Res* 57, 272-278. (1997)
56. Martina Pilátová, Marek Sarisský, Peter Kutschy, Andrej Mirossay, Roman Mezencev, Zalmira Curillová, Miro Suchý, Kazuaki Monde, Ladislav Mirossay, and Jan Mojzis: Cruciferous phytoalexins: antiproliferative effects in T-Jurkat leukemic cells. *Leuk Res* 29, 415-421 (2005)
57. Peter Kutschy, Aneta Salayová, Zalmira Curillová, Tibor Kozár, Roman Mezencev, Jan Mojzis, Martina Pilátová, Eva Balentová, Pavel Pazdera, Marian Sabol, and Michaela Zburová: 2- (substituted phenyl)amino analogs of 1-methoxyspirobrassinol methyl ether: synthesis and anticancer activity. *Bioorg Med Chem* 17, 3698-3712 (2009)

58. Peter Csomós, Istvan Zupkó, Borbala Réthy, Lajos Fodor, George Falkay, and Gabor Bernáth: Isobassinin and its analogues: novel types of antiproliferative agents. *Bioorg Med Chem Lett* 16, 6273-6276 (2006)
59. Tinku Banerjee, James Duhadaway, Paul Gaspari, Erika Sutanto-Ward, David Munn, Andrew Mellor, William Malachowski, George Prendergast, and Alexander Muller: A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase. *Oncogene* 27, 2851-2857 (2008)
60. Chun-Hat Shih, Siu-On Siu, Ricky Ng, Elaine Wong, Lawrence Chiu, Ivan Chu, and Clive Lo: Quantitative analysis of anticancer 3-deoxyanthocyanidins in infected sorghum seedlings. *J Agric Food Chem* 55, 254-259 (2007)
61. Kap-Rang Lee, Nobuyuki Kozukue, Jae-Sook Han, Joon-Hong Park, Eun-Young Chang, Eun-Jung Baek, Jong-Sun Chang, and Mendel Friedman: Glycoalkaloids and metabolites inhibit the growth of human colon (HT29) and liver (HepG2) cancer cells. *J Agric Food Chem* 52, 2832-2839 (2004)
62. Mendel Friedman, Kap-Rang Lee, Hyun-Jeong Kim, In-Seon Lee, and Nobuyuke Kozukue: Anticarcinogenic effects of glycoalkaloids from potatoes against human cervical, liver, lymphoma, and stomach cancer cells. *J Agric Food Chem* 53, 6162-6169 (2005)
63. Sau Lee, Wei Zhang, and Barbara Sanderson: Selective growth inhibition of human leukemia and human lymphoblastoid cells by resveratrol via cell cycle arrest and apoptosis induction. *J Agric Food Chem* 56, 7572-7577 (2008)
64. Po-Lin Kuo, Lien-Chai Chiang, and Chun-Ching Lin: Resveratrol-induced apoptosis is mediated by p53-dependent pathway in Hep G2 cells. *Life Sci* 72, 23-34 (2002)
65. Gregory Gatouillat, Emilie Balasse, Debora Joseph-Pietras, Hamid Morjani, and Claudie Madoulet: Resveratrol induces cell-cycle disruption and apoptosis in chemoresistant B16 melanoma. *J Cell Biochem* 110, 893-902 (2010)
66. Dixan Benitez, Eulalia Pozo-Guisado, Alberto Alvarez-Barrientos, Pedro Fernandez-Salguero, and Enrique Castellón: Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines. *J Androl* 28, 282-293 (2007)
67. Nihal Ahmad, Vaqar Adhami, Farrukh Afaq, Denise Feyes, and Hasan Mukhtar: Resveratrol causes WAF-1/p21-mediated G (1)-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells. *Clin Cancer Res* 7, 1466-1473 (2001)
68. Arianna Kim, Yucui Zhu, Huijie Zhu, Lydia Han, Levy Kopelovich, David Bickers, and Mohammed Athar: Resveratrol inhibits proliferation of human epidermoid carcinoma A431 cells by modulating MEK1 and AP-1 signalling pathways. *Exp Dermatol* 15, 538-546 (2006)
69. Zeev Estrov, Shishir Shishodia, Stefan Faderl, David Harris, Quin Van, Hagop Kantarjian, Moshe Talpaz, and Bharat Aggarwal: Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. *Blood* 102, 987-995 (2003)
70. Andrew Joe, Hui Liu, Masumi Suzui, Muhammet Vural, Danhua Xiao, and Bernard Weinstein: Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. *Clin Cancer Res* 8, 893-903 (2002)
71. Freja Wolter, Bora Akoglu, Antje Clausnitzer, and Jurgen Stein: Downregulation of the cyclin D1/Cdk4 complex occurs during resveratrol-induced cell cycle arrest in colon cancer cell lines. *J Nutr* 131, 2197-2203 (2001)
72. Yun Chen, Sheng-Hong Tseng, Hong-Shiee Lai, and Wei-Jao Chen: Resveratrol-induced cellular apoptosis and cell cycle arrest in neuroblastoma cells and antitumor effects on neuroblastoma in mice. *Surgery* 136, 57-66 (2004)
73. Takayuki Shimizu, Tomonori Nakazato, Ming Xian, Morihiko Sagawa, Yasuo Ikeda, and Mahasiro Kizaki: Resveratrol induces apoptosis of human malignant B cells by activation of caspase-3 and p38 MAP kinase pathways. *Biochem Pharmacol* 71, 742-750 (2006)
74. Alpna Tyagi, Rana Singh, Chapla Agarwal, Sunitha Siriwardana, Robert Sclafani, and Rajesh Agarwal: Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovar-3 cells. *Carcinogenesis* 26, 1978-1987 (2005)
75. Susanne Gatz and Lisa Wiesmüller: Take a break--resveratrol in action on DNA. *Carcinogenesis* 29, 321-332 (2008)
76. Xin He, Yu Wang, Jinbong Zhu, Mohammed Orloff, and Charis Eng: Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling. *Cancer Lett* 301, 168-176 (2011)
77. Yu-Chin Liang, Shu-Huei Tsai, Linda Chen, Shoei-Yn Lin-Shiau, and Lin Jen-Kun: Resveratrol-induced G2 arrest through the inhibition of CDK7 and p34CDC2 kinases in colon carcinoma HT29 cells. *Biochem Pharmacol* 65, 1053-1060 (2003)
78. Agnes Rimando, Muriel Cuendet, Cristian Desmarchelier, Rajendra Mehta, John Pezzuto, and Stephen Duke: Cancer chemopreventive and antioxidant activities of pterostilbene, a naturally occurring analogue of resveratrol. *J Agric Food Chem* 50, 3453-3457 (2002)

79. Agnes Rimando, John Pezzuto, Norman Farnsworth, Thawatchai Santisuk, and Vichai Reutrakul: Revision of the NMR assignments of pterostilbene and dihydrodehydro-diconiferyl alcohol: cytotoxic constituents from *Anogeissus acuminata*. *Nat Prod Lett* 4, 267-272 (1994)
80. Patrick Mannel, Julie Alosi, John Schneider, Debbie McDonald, and David McFadden: Pterostilbene inhibits pancreatic cancer in vitro. *J Gastrointest Surg* 14, 873-879 (2010)
81. Rong-Jane Chen, Chi-Tang Ho, and Ying-Jan Wang: Pterostilbene induces autophagy and apoptosis in sensitive and chemoresistant human bladder cancer cells. *Mol Nutr Food Res* 54, 1819-1832 (2010)
82. Nanjoo Suh, Shiby Paul, Xingpei Hao, Barbara Simi, Hang Xiao, Agnes Rimando, and Bandaru Reddy: Pterostilbene, an active constituent of blueberries, suppresses aberrant crypt foci formation in the azoxymethane-induced colon carcinogenesis model in rats. *Clin Cancer Res* 13, 350-355 (2007)
83. Shiby Paul, Andrew DeCastro, Hong Lee, Amanda Smolarek, Jae So, Barbara Simi, Chung Wang, Renping Zhou, Agnes Rimando, and Nanjoo Suh: Dietary intake of pterostilbene, a constituent of blueberries, inhibits the beta-catenin/p65 downstream signaling pathway and colon carcinogenesis in rats. *Carcinogenesis* 31, 1272-1278 (2010)
84. Yi-Siou Chiou, Mei-Ling Tsai, Ying-Jan Wang, An-Chin Cheng, Wei-Ming Lai, Vladimir Badmaev, Chi-Tang Ho, and Min-Hsiung Pan: Pterostilbene inhibits colorectal aberrant crypt foci (ACF) and colon carcinogenesis via suppression of multiple signal transduction pathways in azoxymethane-treated mice. *J Agric Food Chem* 58, 8833-8841 (2010)
85. Yi-Siou Chiou, Mei-Ling Tsai, Kalyanam Nagabhushanam, Ying-Jan Wang, Chih-Hsiung Wu, Chi-Tang Ho, and Min-Hsiung Pan: Pterostilbene Is More Potent than Resveratrol in Preventing Azoxymethane (AOM)-Induced Colon Tumorigenesis via Activation of the NF-E2-Related Factor 2 (Nrf2)-Mediated Antioxidant Signaling Pathway. *J Agric Food Chem* 59, 2725-2733 (2011)
86. Min-Hsiung Pan, Yen-Hui Chang, Mei-Ling Tsai, Ching-Shu Lai, Sheng-Yow Ho, Vladimir Badmaev, and Chi-Tang Ho: Pterostilbene suppressed lipopolysaccharide-induced up-expression of iNOS and COX-2 in murine macrophages. *J Agric Food Chem* 56, 7502-7509 (2008)
87. Shiby Paul, Agnes Rimando, Hong Lee, Yan Ji, Bandaru Reddy, and Nanjoo Suh: Anti-inflammatory action of pterostilbene is mediated through the p38 mitogen-activated protein kinase pathway in colon cancer cells. *Cancer Prev Res* 2, 650-657 (2009)
88. Wen-Fei Chiou, Ming-Jaw Don, Jyh-Fei Liao, and Bai-Lu Wei: Psoralidin inhibits LPS-induced iNOS expression via repressing Syk-mediated activation of PI3K-IKK-IkB signaling pathways. *Eur J Pharmacol* 650, 102-109 (2011)
89. Raj Kumar, Sowmyalakshmi Srinivasan, Srinivas Koduru, Pallab Pahari, Jurgen Rohr, Natasha Kyprianou, and Chendil Damodaran: Psoralidin, an herbal molecule, inhibits phosphatidylinositol 3-kinase-mediated Akt signaling in androgen-independent prostate cancer cells. *Cancer Prev Res* 2, 234-243 (2009)
90. Raj Kumar, Sowmyalakshmi Srinivasan, Pallab Pahari, Jurgen Rohr, and Chendil Damodaran: Activating stress-activated protein kinase-mediated cell death and inhibiting epidermal growth factor receptor signaling: a promising therapeutic strategy for prostate cancer. *Mol Cancer Ther* 9, 2488-2496 (2010)
91. Keren Hirsch, Michael Danilenko, Judith Giat, Talia Miron, Aharon Rabinkov, Meir Wilchek, David Mirelman, Joseph Levy, and Yoav Sharoni: Effect of purified allicin, the major ingredient of freshly crushed garlic, on cancer cell proliferation. *Nutr Cancer* 38, 245-254 (2000)
92. Dominique Delmas, Eric Solary, and Norbert Latruffe: Resveratrol, a phytochemical inducer of multiple cell death pathways: apoptosis, autophagy and mitotic catastrophe. *Curr Med Chem* 18, 1100-1121 (2011)
93. Chibuike Udenigwe, Vanu Ramprasath, Rotimi Aluko, and Peter Jones: Potential of resveratrol in anticancer and anti-inflammatory therapy. *Nutr Rev* 66, 445-454 (2008)
94. Sandra Ulrich, Freya Wolter, and Jurgen Stein: Molecular mechanisms of the chemopreventive effects of resveratrol and its analogs in carcinogenesis. *Mol Nutr Food Res* 49, 452-461 (2005)
95. Jairam Vanamala, Lavanya Reddivari, Sridhar Radhakrishnan, and Sridhar Tarver: Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways. *BMC Cancer* 10, 238 (2010)
96. Adhip Majumdar, Sanjeev Banerjee, Jyoti Nautiyal, Bhaumik Patel, Vaishali Patel, Jianhua Du, Yingjie Yu, Althea Elliott, Althea Levi, and Fazlul Sarkar: Curcumin synergizes with resveratrol to inhibit colon cancer. *Nutr Cancer* 61, 544-553 (2009)
97. Hung-Yun Lin, Mingzeng Sun, Heng-Yuan Tang, Tessa Simone, Yun-Hsuan Wu, Jennifer Grandis, James Cao, Paul Davis, and Faith Davis: Resveratrol causes COX-2- and p53-dependent apoptosis in head and neck squamous cell cancer cells. *J Cell Biochem* 104, 2131-2142 (2008)
98. Moussa Alkhalaf: Resveratrol-induced apoptosis is associated with activation of p53 and inhibition of protein translation in T47D human breast cancer cells. *Pharmacology* 80, 134-143 (2007)
99. Neetu Singh, Manisha Nigam, Vishal Ranjan, Ramesh Sharma, Anil Balapure, and Srikanta Rath: Caspase mediated enhanced apoptotic action of cyclophosphamide-

- and resveratrol-treated MCF-7 cells. *J Pharmacol Sci* 109, 473-485 (2009)
100. Aristotle Lontas and Herman Yeger: Curcumin and resveratrol induce apoptosis and nuclear translocation and activation of p53 in human neuroblastoma. *Anticancer Res* 24, 987-998 (2004)
101. Min Kim, Laura Trudel, and Gerald Wogan: Apoptosis induced by capsaicin and resveratrol in colon carcinoma cells requires nitric oxide production and caspase activation. *Anticancer Res* 29, 3733-3740 (2009)
102. Qinghe Chen, Suthakar Ganapathy, Karan Singh, Sharmila Shankar, and Rakesh Srivastava: Resveratrol induces growth arrest and apoptosis through activation of FOXO transcription factors in prostate cancer cells. *PLoS One* 5, e15288 (2010)
103. Maaike Van den Berg and Boudewijn Burgering: Integrating opposing signals toward Forkhead box O. *Antioxid Redox Signal* 14, 607-621 (2011)
104. Jen-Liang Su, Ming-Tsan Lin, Chih-Chen Hong, Cheng-Chi Chang, Shine-Gwo Shiah, Cheng-Wen Wu, Szu-Ta Chen, Yat-Pang Chau, and Min-Liang Kuo: Resveratrol induces FasL-related apoptosis through Cdc42 activation of ASK1/JNK-dependent signaling pathway in human leukemia HL-60 cells. *Carcinogenesis* 26, 1-10 (2005)
105. Jin-Taek Hwang, Dong Kwak, Sun Lin, Hye Kim, Young Kim, and Ock Park: Resveratrol induces apoptosis in chemoresistant cancer cells via modulation of AMPK signaling pathway. *Ann N Y Acad Sci* 1095, 441-448 (2007)
106. Sarah Fogarty and Grahame Hardie: Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. *Biochim Biophys Acta* 1804, 581-591 (2010)
107. Reuben Shaw: LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. *Acta Physiol* 196, 65-80 (2009)
108. Suthakar Ganapathy, Qinghe Chen, Karan Singh, Sharmila Shankar, and Rakesh Srivastava: Resveratrol enhances antitumor activity of TRAIL in prostate cancer xenografts through activation of FOXO transcription factor. *PLoS One* 5, e15627 (2010)
109. Christian Billard, Jean-Claude Izard, Viviana Roman, Catherine Kern, Claire Mathiot, Franck Mentz, and Jean-Pierre Kolb: Comparative antiproliferative and apoptotic effects of resveratrol, epsilon-viniferin and vine-shots derived polyphenols (vineatrols) on chronic B lymphocytic leukemia cells and normal human lymphocytes. *Leuk Lymphoma* 43, 1991-2002 (2002)
110. John Schneider, Julie Alosi, Debbie McDonald, and David McFadden: Effects of pterostilbene on melanoma alone and in synergy with inositol hexaphosphate. *Am J Surg* 198, 679-684 (2009)
111. John Schneider, Julie Alosi, Debbie McDonald, and David McFadden: Pterostilbene inhibits lung cancer through induction of apoptosis. *J Surg Res* 161, 18-22 (2010)
112. Julie Alosi, Debbie McDonald, John Schneider, Alicia Privette, and David McFadden: Pterostilbene inhibits breast cancer in vitro through mitochondrial depolarization and induction of caspase-dependent apoptosis. *J Surg Res* 161, 195-201 (2010)
113. Min-Hsiung Pan, Yen-Hui Chang, Vladimir Badmaev, Kalyanam Nagabhushanam, and Chi-Tang Ho: Pterostilbene induces apoptosis and cell cycle arrest in human gastric carcinoma cells. *J Agric Food Chem* 55, 7777-7785 (2007)
114. Zhiqiang Pan, Ameeta Agarwal, Tao Xu, Qin Feng, Scott Baerson, Stephen Duke, and Agnes Rimando: Identification of molecular pathways affected by pterostilbene, a natural dimethylether analog of resveratrol. *BMC Med Genomics* 1, 7 (2008)
115. Woongchon Mar, Kang-Hoon Je, and Eun-Kyoung Seo: Cytotoxic constituents of *Psoralea corylifolia*. *Arch Pharm Res* 24, 211-213 (2001)
116. Yong-Man Yang, Jin-Won Hyun, Min-Sook Sung, Ha-Sook Chung, Byong-Kak Kim, Woo-Hyun Paik, Sam-Sik Kang, and Jae-Gahb Park: The cytotoxicity of psoralidin from *Psoralea corylifolia*. *Planta Med* 62, 353-354 (1996)
117. Sowmyalakshmi Srinivasan, Raj Kumar, Srinivas Koduru, Aaditya Chandramouli, and Chendil Damodaran: Inhibiting TNF-mediated signaling: a novel therapeutic paradigm for androgen independent prostate cancer. *Apoptosis* 15, 153-161 (2010)
118. Hisashi Matsuda, Sachie Kiyohara, Sachiko Sugimoto, Shin Ando, Seikou Nakamura, and Masayuki Yoshikawa: Bioactive constituents from Chinese natural medicines. XXXIII. Inhibitors from the seeds of *Psoralea corylifolia* on production of nitric oxide in lipopolysaccharide-activated macrophages. *Biol Pharm Bull* 32, 147-149 (2009)
119. Eun-Kyung Kim, Kang-Beom Kwon, Byung-Cheul Shin, Eun-A Seo, Young-Rae Lee, Jong-Suk Kim, Jin-Woo Park, Byung-Hyun Park, and Do-Gon Ryu: Scopoletin induces apoptosis in human promyeloleukemic cells, accompanied by activations of nuclear factor kappaB and caspase-3. *Life Sci* 77, 824-836 (2005)
120. Olen Domon, Lynda McGarrity, Michelle Bishop, Makoto Yoshioka, James Chen, and Suzanne Morris: Evaluation of the genotoxicity of the phytoestrogen, coumestrol, in AHH-1 TK (+/-) human lymphoblastoid cells. *Mutat Res* 474, 129-137 (2001)

121. Lavanya Reddivari, Jairam Vanamala, Stephen Safe, and Creighton Miller: The bioactive compounds alpha-chaconine and gallic acid in potato extracts decrease survival and induce apoptosis in LNCaP and PC3 prostate cancer cells. *Nutr Cancer* 62, 601-610 (2010)
122. Lavanya Reddivari, Jairam Vanamala, Sudhakar Chintharlapalli, Stephen Safe, and Creighton Miller: Anthocyanin fraction from potato extracts is cytotoxic to prostate cancer cells through activation of caspase-dependent and caspase-independent pathways. *Carcinogenesis* 28, 2227-2235 (2007)
123. Wenlu Zhang, Minwen Ha, Yuehua Gong, Ying Xu, Nannan Dong, and Yuan Yuan: Allicin induces apoptosis in gastric cancer cells through activation of both extrinsic and intrinsic pathways. *Oncol Rep* 24, 1585-1592 (2010)
124. Suby Oommen, Ruby Anto, Gopal Srinivas, and Gopal Karunakaran: Allicin (from garlic) induces caspase-mediated apoptosis in cancer cells. *Eur J Pharmacol* 485, 97-103 (2004)
125. Wolf Bat-Chen, Tal Golan, Irena Peri, Zvi Ludmer, and Betty Schwartz: Allicin purified from fresh garlic cloves induces apoptosis in colon cancer cells via Nrf2. *Nutr Cancer* 62, 947-957 (2010)
126. Talia Miron, Meir Wilchek, Ayala Sharp, Yoshihito Nakagawa, Makoto Naoi, Yoshinori Nozawa, and Yukihiko Akao: Allicin inhibits cell growth and induces apoptosis through the mitochondrial pathway in HL60 and U937 cells. *J Nutr Biochem* 19, 524-535 (2008)
127. Fabian Arditti, Aharon Rabinkov, Talia Miron, Yair Reisner, Alain Berrebi, Meir Wilchek, and David Mirelman: Apoptotic killing of B-chronic lymphocytic leukemia tumor cells by allicin generated *in situ* using a rituximab-alliinase conjugate. *Mol Cancer Ther* 4, 325-331 (2005)
128. Youn-Hee Joung, Eun-Joung Lim, Mi-Sun Kim, So Lim, So-Young Yoon, Young Lim, Young Yoo, Sang-Kyu Ye, Taekyu Park, Ill-Min Chung, Ki-Yeol Bae, and Young Mok Yang: Enhancement of hypoxia-induced apoptosis of human breast cancer cells via STAT5b by momilactone B. *Int J Oncol* 33, 477-484 (2008)
129. Seung Lee, Ill-Min Chung, Yeong Jin, Yeon Song, Su Seo, Bong Park, Kwang Cho, Ki Yoo, Tae-Hyun Kim, Su-Bog Yee, Yoe-Sik Bae, and Young Yoo: Momilactone B, an allelochemical of rice hulls, induces apoptosis on human lymphoma cells (Jurkat) in a micromolar concentration. *Nutr Cancer* 60, 542-551 (2008)
130. Sun-Jung Kim, Hae-Ryong Park, Eunju Park, and Seung-Cheol Lee: Cytotoxic and antitumor activity of momilactone B from rice hulls. *J Agric Food Chem* 55, 1702-1706 (2007)
131. Mathias Leber and Thomas Efferth: Molecular principles of cancer invasion and metastasis (review). *Int J Oncol* 34, 881-895 (2009)
132. Ming-Kun Lu, Yuan-Wei Shih, Tzu-Tsung Chang Chien, Li-Heng Fang, Hsiang-Ching Huang, and Pin-Shern Chen: α -Solanine inhibits human melanoma cell migration and invasion by reducing matrix metalloproteinase-2/9 activities. *Biol Pharm Bull* 33, 1685-1691 (2010)
133. Yuan-Wei Shih, Pin-Shern Chen, Cheng-Hsun Wu, Ya-Fang Jeng, and Chau-Jong Wang: Alpha-chaconine-reduced metastasis involves a PI3K/Akt signaling pathway with downregulation of NF- κ B in human lung adenocarcinoma A549 cells. *J Agric Food Chem* 55, 11035-11043 (2007)
134. Ming-Kun Lu, Pei-Hsieng Chen, Yuan-Wei Shih, Ya-Ting Chang, En-Tze Huang, Cheng-Ruei Liu, and Pin-Shern Chen: alpha-Chaconine inhibits angiogenesis *in vitro* by reducing matrix metalloproteinase-2. *Biol Pharm Bull* 33, 622-630 (2010)
135. Eun-Wha Son, Sung-Ji Mo, Dong-Kwon Rhee, and Suhkneung Pyo: Inhibition of ICAM-1 expression by garlic component, allicin, in gamma-irradiated human vascular endothelial cells via downregulation of the JNK signaling pathway. *Int Immunopharmacol* 6, 1788-1795 (2006)
136. Min-Hsiung Pan, Yi-Siou Chiou, Wei-Jen Chen, Ju-Ming Wang, Vladimir Badmaev, and Chi-Tang Ho: Pterostilbene inhibited tumor invasion via suppressing multiple signal transduction pathways in human hepatocellular carcinoma cells. *Carcinogenesis* 30, 1234-1242 (2009)
137. Min-Hsiung Pan, Ying-Ting Lin, Chih-Li Lin, Chi-Shiang Wei, Chi-Tang Ho, and Wei-Jen Chen: Suppression of Heregulin- β 1/HER2-Modulated Invasive and Aggressive Phenotype of Breast Carcinoma by Pterostilbene via Inhibition of Matrix Metalloproteinase-9, p38 Kinase Cascade and Akt Activation. *Evid Based Complement Alternat Med* (2009)
138. Miaw-Sheue Tsai, Lisa Shamon-Taylor, Inderjit Mehmi, Careen Tang, and Ruth Lupu: Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer. *Oncogene* 22, 761-768 (2003)
139. Feng-Yao Tang, En-Pei Isabel Chiang, and Ya-Chi Sun: Resveratrol inhibits heregulin-beta1-mediated matrix metalloproteinase-9 expression and cell invasion in human breast cancer cells. *J Nutr Biochem* 19, 287-294 (2008)
140. Pamela Magee, Hugh McGlynn, and Ian Rowland: Differential effects of isoflavones and lignans on invasiveness of MDA-MB-231 breast cancer cells *in vitro*. *Cancer Lett* 208, 35-41 (2004)
141. Sara Javid, Amy Moran, Adelaide Carothers, Mark Redston, and Monica Bertagnolli: Modulation of tumor formation and intestinal cell migration by estrogens in the Apc (Min/+) mouse model of colorectal cancer. *Carcinogenesis* 26, 587-595 (2005)

142. Rong Pan, Yue Dai, Xing-Hua Gao, Dan Lu, and Yu-Feng Xia: Inhibition of vascular endothelial growth factor-induced angiogenesis by scopoletin through interrupting the autophosphorylation of VEGF receptor 2 and its downstream signaling pathways. *Vascul Pharmacol* 54, 18-28 (2011)
143. Georgi Nikov, Nancy Hopkins, Stephen Boue, and William Alworth: Interactions of dietary estrogens with human estrogen receptors and the effect on estrogen receptor-estrogen response element complex formation. *Environ Health Perspect* 108, 867-872 (2000)
144. Matthew Burow, Stephen Boue, Bridgette Collins-Burow, Lilia Melnik, Bich Duong, Carol Carter-Wientjes, Shuanfang Li, Thomas Wiese, Thomas Cleveland, and John McLachlan: Phytochemical glyceollins, isolated from soy, mediate antihormonal effects through estrogen receptor alpha and beta. *J Clin Endocrinol Metab* 86, 1750-1758 (2001)
145. Virgilio Salvo, Stephen Boue, Juan Fonseca, Steven Elliott, Cynthia Corbitt, Bridgette Collins-Burow, Tyler Curiel, Sudesh Srivastav, Betty Shih, Carol Carter-Wientjes, Charles Wood, Paul Erhardt, Barbara Beckman, John McLachlan, Thomas Cleveland, and Matthew Burow: Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis. *Clin Cancer Res* 12, 7159-7164 (2006)
146. Nathaniel Mead: Mining for glyceollins. *Environ Health Perspect* 115, A189 (2007)
147. Andrew Freedman, Binbing Yu, Mitchell Gail, Joseph Costantino, Barry Graubard, Victor Vogel, Garnet Anderson, and Wortia McCaskill-Stevens: Benefit/Risk Assessment for Breast Cancer Chemoprevention with Raloxifene or Tamoxifen for Women Age 50 Years or Older. *J Clin Oncol* (2011)
148. Charles Wood, Thomas Clarkson, Susan Appt, Adrian Franke, Stephen Boue, Matthew Burow, Thomas McCoy, and Mark Cline: Effects of soybean glyceollins and estradiol in postmenopausal female monkeys. *Nutr Cancer* 56, 74-81 (2006)
149. Kenneth Setchell: Soy isoflavones--benefits and risks from nature's selective estrogen receptor modulators (SERMs). *J Am Coll Nutr* 20, 354S-362S (2001)
150. Shengbao Feng, Chin Saw, Yuan Lee, and Dejian Huang: Novel process of fermenting black soybean (*Glycine max* (L.) Merrill) yogurt with dramatically reduced flatulence-causing oligosaccharides but enriched soy phytoalexins. *J Agric Food Chem* 56, 10078-10084 (2008)
151. Stephen Boue, Syreeta Tilghman, Steven Elliott, Carla Zimmerman, Williams KY, Florastina Payton-Stewart, Allen Miraflor, Melanie Howell, Betty Shih, Carol Carter-Wientjes, Chris Segar, Barbara Beckman, Thomas Wiese, Thomas Cleveland, John McLachlan, and Matthew Burow: Identification of the potent phytoestrogen glycinol in elicited soybean (*Glycine max*). *Endocrinology* 150, 2446-2453 (2009)
152. Florastina Payton-Stewart, Norberta Schoene, Young Kim, Matthew Burow, Thomas Cleveland, Stephen Boue, and Thomas Wang: Molecular effects of soy phytoalexin glyceollins in human prostate cancer cells LNCaP. *Mol Carcinog* 48, 862-871 (2009)
153. Carla Zimmerman, Syreeta Tilghman, Stephen Boue, Virgilio Salvo, Steven Elliott, K.Y. Williams, Elena Skripnikova, Hasina Ashe, Florastina Payton-Stewart, Lyndsay Vanhoy-Rhodes, Juan Fonseca, Cynthia Corbitt, Bridgette Collins-Burow, Melanie Howell, Michelle Lacey, Betty Shih, Carol Carter-Wientjes, Thomas Cleveland, John McLachlan, Thomas Wiese, Barbara Beckman, and Matthew Burow: Glyceollin I, a novel antiestrogenic phytoalexin isolated from activated soy. *J Pharmacol Exp Ther* 332, 35-45 (2010)
154. Florastina Payton-Stewart, Rahul Khupse, Stephen Boué, Steven Elliott, Carla Zimmermann, Elena Skripnikova, Hasina Ashe, Syreeta Tilghman, Barbara Beckman, Thomas Cleveland, John McLachlan, Deepak Bhatnagar, Thomas Wiese, Paul Erhardt, and Matthew Burow: Glyceollin I enantiomers distinctly regulate ER-mediated gene expression. *Steroids* 75, 870-878 (2010)
155. Mark Cline and Charles Wood: Estrogen/isoflavone interactions in cynomolgus macaques (*Macaca fascicularis*). *Am J Primatol* 71, 722-731 (2009)
156. Donna Dixon-Shanies and Nina Shaikh: Growth inhibition of human breast cancer cells by herbs and phytoestrogens. *Oncol Rep* 6, 1383-1387 (1999)
157. Chanfeng Wang and Mindy Kurzer: Effects of phytoestrogens on DNA synthesis in MCF-7 cells in the presence of estradiol or growth factors. *Nutr Cancer* 31, 90-100 (1998)
158. John Ashby, Helen Tinwell, Anthony Soames, and John Foster: Induction of hyperplasia and increased DNA content in the uterus of immature rats exposed to coumestrol. *Environ Health Perspect* 107, 819-822 (1999)
159. Liza Valentin-Blasini, Benjamin Blount, Samuel Caudill, and Larry Needham: Urinary and serum concentrations of seven phytoestrogens in a human reference population subset. *J Expo Anal Environ Epidemiol* 13, 276-282 (2003)
160. Pamela Horn-Ross, Stephen Barnes, Valerie Lee, Christine Collins, Peggy Reynolds, Marion Lee, Susan Stewart, Alison Canchola, Landon Wilson, and Kenneth Jones: Reliability and validity of an assessment of usual phytoestrogen consumption (United States). *Cancer Causes Control* 17, 85-93 (2006)
161. Stephan Mueller, Margret Kling, Poppy Firzani, Astrid Mecky, Eric Duranti, Jacqueline Shields-Botella,

Remi Delansorne, Thomas Broschard, and Peter-Jurgen Kramer: Activation of estrogen receptor alpha and ERbeta by 4-methylbenzylidene-camphor in human and rat cells: comparison with phyto- and xenoestrogens. *Toxicol Lett* 142, 89-101 (2003)

162. Farzana Walcott, Michael Hauptmann, Cherie Duphorne, Patricia Pillow, Sara Strom, and Alice Sigurdson: A case-control study of dietary phytoestrogens and testicular cancer risk. *Nutr Cancer* 44, 44-51 (2002)

163. Sara Strom, Yuko Yamamura, Cherie Duphorne, Margaret Spitz, Richard Babaian, Patricia Pillow, and Stephen Hursting: Phytoestrogen intake and prostate cancer: a case-control study using a new database. *Nutr Cancer* 33, 20-25 (1999)

164. Richard Hoffman: Potent inhibition of breast cancer cell lines by the isoflavonoid genistein: comparison with genistein. *Biochem Biophys Res Commun* 211, 600-606 (1995)

165. Efrosini Katsanou, Maria Halabalaki, Nektarios Aliagannis, Sofia Mitakou, Alexios-Leandros Skaltsounis, Xanthippi Alexi, Harris Pratsinis, and Michael Alexis: Cytotoxic effects of 2-arylbenzofuran phytoestrogens on human cancer cells: modulation by adrenal and gonadal steroids. *J Steroid Biochem Mol Biol* 104, 228-236 (2007)

166. Barry Gehm, Joanne McAndrews, Pei-Yu Chien, and Larry Jameson: Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. *Proc Natl Acad Sci USA* 94, 14138-14143 (1997)

167. Jennifer Bowers, Valentyn Tyulmenko, Sarah Jernigan, and Carolyn Klinge: Resveratrol acts as a mixed agonist/ antagonist for estrogen receptors alpha and beta. *Endocrinology* 141, 3657-3667 (2000)

168. Takako Sakamoto, Hyogo Horiguchi, Etsuko Oguma, and Fujio Kayama: Effects of diverse dietary phytoestrogens on cell growth, cell cycle and apoptosis in estrogen-receptor-positive breast cancer cells. *J Nutr Biochem* 21, 856-864 (2010)

169. Fang Lu, Muhammad Zahid, Cheng Wang, Muhammad Saeed, and Ercole Cavaleri, and Eleanor Rogan: Resveratrol prevents estrogen-DNA adduct formation and neoplastic transformation in MCF-10F cells. *Cancer Prev Res* 1, 135-145 (2008)

170. Andreas Papoutsis, Sarah Lamore, Georg Wondrak, Ornella Selmin, and Donato Romagnolo: Resveratrol prevents epigenetic silencing of BRCA-1 by the aromatic hydrocarbon receptor in human breast cancer cells. *J Nutr* 140, 1607-1614 (2010)

171. Naoki Harada, Kiyotaka Atarashi, Yohei Murata, Ryoichi Yamaji, Yoshihisa Nakano, and Hiroshi Inui:

Inhibitory mechanisms of the transcriptional activity of androgen receptor by resveratrol: Implication of DNA binding and acetylation of the receptor. *J Steroid Biochem Mol Biol* 123, 65-70 (2011)

172. Stephanie Degner, Andreas Papoutsis, Ornella Selmin, and Donato Romagnolo: Targeting of aryl hydrocarbon receptor-mediated activation of cyclooxygenase-2 expression by the indole-3-carbinol metabolite 3,3'-diindolylmethane in breast cancer cells. *J Nutr* 139, 26-32 (2009)

173. Thomas Wang, Tamaro Hudson, Tien-Chung Wang, Connie Remsberg, Neal Davies, Yoko Takahashi, Young Kim, Harold Seifried, Bryan Vinyard, Susan Perkins, and Stephen Hursting: Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivo. *Carcinogenesis* 29, 2001-2010 (2008)

174. Ken Itoh, Tomoki Chiba, Satoru Takahashi, Tetsuro Ishii, Kazuhiko Igarashi, Yasutake Katoh, Tatusya Oyake, Noto Hayashi, Kimihiko Satoh, Ichiro Hatayama, Masayuki Yamamoto, and Yo-ichi Nabeshima: An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. *Biochem Biophys Res Commun* 236, 313-322 (1997)

175. Woo-Sik Jeong, Mira Jun, and Ah-Ng Kong: Nrf2: a potential molecular target for cancer chemoprevention by natural compounds. *Antioxid Redox Signal* 8, 99-106 (2006)

176. John Hayes, Michael Kelleher, and Ian Eggleston: The cancer chemopreventive actions of phytochemicals derived from glucosinolates. *Eur J Nutr* 47, 73-88 (2008)

177. Anil Jaiswal: Nrf2 signaling in coordinated activation of antioxidant gene expression. *Free Radic Biol Med* 36, 1199-207 (2004)

178. Sung-Jin Lee, Kung-Woo Nam, and Woongchon Mar: Induction of quinone reductase activity by psoralidin isolated from *Psoralea corylifolia* in mouse hepa 1c1c7 cells. *Arch Pharm Res* 32, 1061-1065 (2009)

179. Nira Izigov, Nahid Farzam, and Naphtali Savion: S-allylmercapto-N-acetylcysteine up-regulates cellular glutathione and protects vascular endothelial cells from oxidative stress. *Free Radic Biol Med* 50, 1131-1139 (2011)

180. Limor Horev-Azaria, Shlomit Eliav, Nira Izigov, Sarah Pri-Chen, David Mirelman, Talia Miron, Aharon Rabinkov, Meir Wilchek, Jasmine Jacob-Hirsch, Ninette Amariglio, and Naphtali Savion: Allicin up-regulates cellular glutathione level in vascular endothelial cells. *Eur J Nutr* 67-74 (2009)

181. Varsha Singh, Daurat Belloir, Marie-Helen Siess MH, and Anne Le Bon: Inhibition of carcinogen-induced DNA damage in rat liver and colon by garlic powders with varying alliin content. *Nutr Cancer* 55, 178-184 (2006)

182. Christine Belloir, Varsha Singh, Caroline Daurat, Marie-Helen Siess, and Anne Le Bon: Protective effects of

garlic sulfur compounds against DNA damage induced by direct- and indirect-acting genotoxic agents in HepG2 cells. *Food Chem Toxicol* 44, 827-834 (2006)

183. Bertrand Piver, Francois Berthou, Yvonne Dreano, and Daniele Lucas: Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. *Toxicol Lett* 125, 83-91 (2001)

184. Dominique Delmas, Allan Lancon, Didier Colin, Brigitte Jannin, and Norbert Latruffe: Resveratrol as a chemopreventive agent: a promising molecule for fighting cancer. *Curr Drug Targets* 7, 423-442 (2006)

185. Sherry Chow, Linda Garland, Chiu-Hsieh Hsu, Donna Vining, Wade Chew, Jessica Miller, Marjorie Perloff, James Crowell, and David Alberts: Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. *Cancer Prev Res* 3, 1168-1175 (2010)

186. Henry Ciolino, Phillip Daschner, and Grace Yeh: Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor. *Cancer Res* 58, 5707-5712 (1998)

187. Maura Floreani, Eleonora Napoli, Luigi Quintieri, and Pietro Palatini: Oral administration of trans-resveratrol to guinea pigs increases cardiac DT-diaphorase and catalase activities, and protects isolated atria from menadione toxicity. *Life Sci* 72, 2741-2750 (2003)

188. Hanna Szafer, Michal Cichocki, Damian Brauze, and Wanda Baer-Dubowska: Alteration in phase I and II enzyme activities and polycyclic aromatic hydrocarbons-DNA adduct formation by plant phenolics in mouse epidermis. *Nutr Cancer* 48, 70-77 (2004)

189. Donatella Canistro, Barbara Bonamassa, Laura Pozzetti, Andrea Sapone, Sherif Abdel-Rahman, Gian Biagi, and Moreno Paolini: Alteration of xenobiotic metabolizing enzymes by resveratrol in liver and lung of CD1 mice. *Food Chem Toxicol* 47, 454-461 (2009)

190. Juan Rubiolo, Gilles Mithieux, and Felix Vega: Resveratrol protects primary rat hepatocytes against oxidative stress damage: activation of the Nrf2 transcription factor and augmented activities of antioxidant enzymes. *Eur J Pharmacol* 591, 66-72 (2008)

191. Anupam Bishayee, Kendra Barnes, Deepak Bhatia, Altaf Darvesh, and Richard Carroll: Resveratrol suppresses oxidative stress and inflammatory response in diethylnitrosamine-initiated rat hepatocarcinogenesis. *Cancer Prev Res* 3, 753-763 (2010)

192. Michael Haack, Maria Löwinger, Doris Lippmann, Anna Kipp, Eleonora Pagnotta, Renato Iori, Berhard Monien, Hansruedi Glatt, Martin Brauer, Ludger Wessjohann, and Regina Brigelius-Flohé: Breakdown products of neoglucobrassicin inhibit activation of Nrf2 target genes mediated by myrosinase-derived glucoraphanin hydrolysis products. *Biol Chem* 391, 1281-1293 (2010)

193. Paolo Perocco, Giorgio Bronzetti, Donatella Canistro, Luca Valgimigli, Andrea Sapone, Alessandra Affatato, Gian Pedulli, Laura Pozzetti, Massimiliano Broccoli, Renato Iori, Jessica Barillari, Valeriana Sblendorio, Marvin Legator, Moreno Paolini, and Sherif Abdel-Rahman: Glucoraphanin, the bioprecursor of the widely extolled chemopreventive agent sulforaphane found in broccoli, induces phase-I xenobiotic metabolizing enzymes and increases free radical generation in rat liver. *Mutat Res* 595, 125-136 (2006)

194. Ahmad Abdull Razis, Manuele Bagatta, Gina De Nicola, Renato Iori, and Costas Ioannides: Intact glucosinolates modulate hepatic cytochrome P450 and phase II conjugation activities and may contribute directly to the chemopreventive activity of cruciferous vegetables. *Toxicology* 277, 74-85 (2010)

195. Elisabeth Wenzel, Tomislav Soldo, Helmut Erbersdobler, and Veronika Somoza: Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. *Mol Nutr Food Res* 249, 482-494 (2005)

196. Shunso Hatono, Arnie Jimenez, and Michael Wargovich: Chemopreventive effect of S-allylcysteine and its relationship to the detoxification enzyme glutathione S-transferase. *Carcinogenesis* 17, 1041-1044 (1996)

197. David Boocock, Guy Faust, Ketan Patel, Anna Schinas, Victoria Brown, Murray Ducharme, Tristan Booth, James Crowell, Marjorie Perloff, Andreas Gescher, William Steward, and Dean Brenner: Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. *Cancer Epidemiol Biomarkers Prev* 16, 1246-1252 (2007)

198. Ketan Patel, Victoria Brown, Donald Jones, Robert Britton, David Hemingway, Andrew Miller, Kevin West, Tristan Booth, Marjorie Perloff, James Crowell, Dean Brenner, William Steward, Andreas Gescher, and Karen Brown: Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. *Cancer Res* 70, 7392-7399 (2010)

199. Victoria Brown, Ketan Patel, Maria Viskaduraki, James Crowell, Marjorie Perloff, Tristan Booth, Grygoriy Vasilinin, Ananda Sen, Anna Schinas, Gianfranca Piccirilli, Karen Brown, William Steward, Andreas Gescher, and Dean Brenner: Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. *Cancer Res* 70, 9003-11 (2010)

Abbreviations: ACF: aberrant crypt foci; AFB1: aflatoxin B1; AhR: aromatic hydrocarbon receptor; AIPC: androgen independent prostate cancer; AP-1: activator protein-1; DMBA: 7, 12-dimethylbenz (a)anthracene; AR: androgen receptor; ARE: antioxidant response element; ATM: ataxia telangiectasia mutated; ATR: ataxia telangiectasia and Rad3-related; AOM: azoxymethane; AMPK: 5' adenosine monophosphate-activated protein kinase; Bax: Bcl-2

associated X protei;, Bcl-2: B-cell lymphoma-2; Cyt-c: cytochrome-c; DADS: diallyl disulfide; DMH: 1,2-dimethylhydrazine; DHT: Dihydrotestosterone; ECM: extracellular matrix; EGFR: epidermal growth factor receptor; EGF: epidermal growth factor; ER: estrogen receptor; ERE: estrogen response element; Fas: apoptosis stimulating fragment; FKHRL1: forkhead transcription factor-1; FOXO: forkhead box O; GADD: growth arrest DNA-damage-inducible; GCLM: glutamate-cysteine-ligase modifier; GSH: glutathione; GST: glutathione-s-transferase; GRP: glucoraphanin; ICAM: intercellular adhesion molecule; IDO: ERK-1: extracellular signal-regulated kinase (ERK)-1; IGF-1R: insulin-like growth factor-1 receptor; iNOS: inducible nitric oxide synthase; IDO: idolamine 2,3-dioxygenase; IL: interleukin; JNK: c-Jun N-terminal kinase; MAPK: mitogen-activated protein kinase; MEK-1: mitogen-activated protein kinase-extracellular signal-regulated kinase-1; MMP: matrix metallo proteinases; MMS: methylmethane sulfonate; mTOR: mammalian target of rapamycin; NDMA: N-nitrosodimethylamine; NFkappaB: nuclear factor kappa beta; NQO1: NAD (P)H:quinine oxidoreductase; Nrf2: nuclear factor-erythroid2-related factor2; PARP: poly (ADP-ribose) polymerase; PCNA: proliferating cell nuclear antigen; PI3K: phosphatidylinositol 3-kinase; PR: progesterone reeptor; PSA: prostate-specific antigen; QR: quinone reductase; TNFalpha: tumor necrosis factor-alpha; TRAIL: TNF-related apoptosis-inducing ligand; Ras: rat sarcoma; Rb: retinoblastoma; ROS: reactive oxygen species SAPK: stress-activated protein kinase; SFN: sulforaphane; TGF: transforming growth factor; TFF1: trefoil factor-1; UGT: uridine 5'-diphosphoglucuronosyltransferase; VEGF: vascular endothelial growth factor; VEGFR: vascular endothelial growth factor receptor; XRE: xenobiotic response element

Key Words: Phytoalexins, Plants, Nutrition, Cancer process, Cancer prevention, Review

Send correspondence to: Donato F. Romagnolo, Department of Nutritional Sciences and Arizona Cancer Center, Shantz Bldg Rm 303, The University of Arizona, Tucson, AZ, 85721-0038, Tel: 520-626-9108, Fax: 520-621-9446, E-mail: donato@u.arizona.edu